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ABSTRACT 
 
 Fanconi Anemia (FA) is a rare autosomal and X-linked disease characterized by 
multiple congenital abnormalities, progressive bone marrow failure, and cancer 
predisposition. FA is caused by a biallelic mutation of any one of 21 genes; the proteins 
encoded by these genes regulate the removal of DNA interstrand crosslinks (ICLs) and 
are essential for maintaining chromosomal stability. This pathway is tightly regulated by 
posttranslational modifications (PTMs) such as ubiquitination and phosphorylation. 
Several kinases such as ATM, ATR and PLK1 have been linked to the pathway but no 
phosphatase has been firmly linked to the pathway. PTEN is a duel specificity 
phosphatase, capable of removing phosphate groups from phosphorylated lipids and also 
phosphorylated serine, threonine, and tyrosine residues, and it has recently been 
connected to genome stability. The goal of this research was to determine mechanistically 
PTEN’s role in DNA repair. Through this research, we have established that PTEN is 
necessary for a functional FA pathway, and this is dependent on its protein phosphatase 
activity and its ability to be SUMOylated on residue K254. 
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PREFACE 
The following dissertation has been prepared in manuscript format. Chapter 1, 
“Mechanistic Insight into the function of Nuclear PTEN” was prepared for publication in 
Cell Cycle and is a review encapsulating our current understanding of the regulation and 
function of nuclear PTEN. Chapter 2, “The PTEN phosphatase functions cooperatively 
with the Fanconi anemia proteins in DNA crosslink repair” was prepared for publication 
in Scientific Reports. Chapter 3, “PTEN SUMOylation is important for DNA crosslink 
repair” was prepared for submission to Oncotarget. 
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Abstract: 
PTEN is a tumor suppressor protein frequently mutated in cancers. Its main tumor 
suppressor function is localized in the cytoplasm, suppressing the PI3K/AKT signaling 
pathway by dephosphorylating phosphatidylinositol-3,4,5-triphosphate to 
phosphatidylinositol-4,5-bisphosphate. A separate nuclear function for PTEN has 
recently emerged, and there have been great efforts to understand how PTEN operates to 
preserve genome integrity. Here we have summarized the recent findings examining the 
role of nuclear PTEN.   
 
Introduction: 
Phosphatase and tensin homolog (PTEN) is a bona fide tumor suppressor gene located on 
chromosome 10, and it has been shown to regulate cellular proliferation and cell growth 
[1, 2]. PTEN encodes a dual specificity phosphatase capable of removing phosphate 
groups from both proteins and lipids [3, 4]. In 1997 Li et al. detected homozygous 
deletions, frameshifts, and nonsense mutations in PTEN in 63% of glioblastoma cell 
lines, 100% of prostate cancer cell lines, and 10% of breast cancer cell lines, leading to 
the categorization of PTEN as a tumor suppressor gene [1].  It was originally thought that 
the sole tumor suppressor function of PTEN was to dephosphorylate the lipid second 
messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), a potent activator of the AKT 
kinase [4]. PIP3 is produced by the phosphorylation of 
phosphatidylinositol-4,5-bisphosphate (PIP2) by phosphatidylinositol 3-kinase (PI3K) 
upon external or internal stimulation. The AKT kinase then interacts with PIP3 for its 
activation, and targets many downstream signal transduction pathways preventing 
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apoptosis signaling, and thus promoting cell growth [5]. Loss of PTEN lipid phosphatase 
function leads to de-repression of the PI3K/AKT pathway and the stimulation of cell 
growth and survival [2, 6]. While plasma membrane localized PTEN function is central 
to tumor suppression, recent studies have established that PTEN has PI3K/AKT-
independent nuclear tumor suppressive functions [7, 8]. Many of the mutations found in 
tumors are found in the phosphatase domain of PTEN, inactivating its phosphatase 
function, but mutations are also found outside of this domain, many of which result in 
truncated mutants lacking the carboxyl terminal of PTEN [1, 9, 10]. This indicates a 
tumor suppressor function independent of its lipid phosphatase activity and of its known 
role to antagonize the PI3K/AKT pathway. Recently there have been great efforts to 
acquire a better understanding of the role of PTEN outside its PI3K antagonist role, 
focusing on its nuclear function as a guardian of the genome.  
 Cells without functional PTEN display increased chromosome instability with a 
high frequency of DNA double strand breaks (DSBs) [10]. Important roles for PTEN in 
the regulation of cell cycle progression and the maintenance of chromosome stability 
have also recently been established [10-18].  This review will discuss the recent findings 
of PTEN nuclear function, independent of its lipid phosphatase activity. Here we will 
discuss PTEN’s involvement in genome protection through its regulation of DNA 
replication, the cell cycle, stabilization of chromatin, and finally its own regulation via 
posttranslational modification.   
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PTEN: 
PTEN encodes a 403 amino acid protein comprised of an N-terminal phosphatase domain 
and a C-terminal C2 domain (Figure 1).  While the majority of the focus has been on the 
phosphatase domain, the C2 domain has also shown its importance with securing the 
genome through various protein-protein interactions [10, 13, 14, 16, 18].  C2 domains are 
known to interact and localize to cell membranes, thus promoting PTEN’s lipid 
phosphatase activity [19]. Lastly PTEN C-terminus contains many phosphorylation sites 
that are important for its cellular localization and stability. Many of these 
phosphorylation sites are located in or around a PEST motif, which targets proteins with 
short intracellular half-life for proteolytic degradation [20]. 
 
PTEN and Chromatin Structure:  
It was first shown in 2007 that PTEN has a nuclear tumor suppressor function 
independent of its canonical lipid phosphatase activity [10]. Mutations leading to 
truncation and loss of the C2 domain are known to cause Cowden syndrome, an 
autosomal dominant disease characterized by increased susceptibility to breast and 
thyroid cancers [9]. Additionally, PTEN mutations that retain intact lipid phosphatase 
activity have been found in multiple cancers resulting in intensive investigation of a 
novel tumor suppressor function. PTEN was shown to physically interact with the 
kinetochore subunit CENP-C, implicating it in centromere stability. Shen et al observed 
an increase in centromere like aberrations such as translocations in mouse embryonic 
fibroblast MEFs-PTEN-/- compared to MEFs-PTEN+/+ [10]. Translocations can be easily 
visualized in a mouse model due to their chromosomes being acrocentric [21]. 
 
 
6 
 
 
 
 
 
Figure 1. Domain Architecture and Structure of PTEN. 
PTEN is comprised of an amino terminal phosphatase domain harboring the important 
catalytic residues C124 and G129. When the cystine is mutated to a serine PTEN is 
phosphatase dead while mutating the glycine to a glutamic acid, PTEN is only lipid 
phosphatase inactive. The carboxyl C2 domain contains the lysine that is SUMOylated 
and is shown to be important for DNA repair and the PEST (Proline, Glutamic acid, 
Serine, Threonine) motif [8, 11]. 
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Interestingly, it has previously been shown that gene transcription profiles are altered in 
cells lacking PTEN [22]. This led the Shen group to investigate PTENs role in gene 
expression and regulation by comparing chromatin architecture in PTEN-/- MEFs to 
PTEN+/+ MEFs [14]. They discovered that PTEN interacts with the carboxyl terminus of 
histone 1 (H1) via PTEN’s C2 domain [14]. H1 is a histone linker connecting 
nucleosome complexes thus regulating the higher order of chromatin architecture in the 
nucleus [23]. Nucleosomes are the core subunits of chromatin, around which DNA is 
wrapped and are comprised of 2 copies each of histones H2A, H2B, H3, and H4 [24, 25]. 
While the posttranslational modifications localized to the N- and C- terminals of the 
histones are important for gene accessibility or DNA repair, protein-protein interactions 
form complexes creating heterochromatin or gene silenced regions [26, 27]. An example 
of a protein known to interact with histones, Heterochromatin protein 1, HP1α, is known 
to bind to methylated H3 and H1 thus condensing chromatin [27]. Chen et al. showed that 
PTEN stabilizes the H1-HP1α protein complex, causing chromatin condensing into 
heterochromatin and genes silencing [14]. This new role of PTEN as a modulator of 
chromatin could be crucial for a better understanding of PTEN deficient cancers and their 
gene expression profiles.  Also importantly, PTEN stabilization of centromeres through 
its interaction with the centromere specific binding protein, CENP-C, prevents 
chromosomal aberrations including radials and translocations that could lead to cancers 
and diseases [10]. CENP-C is an essential component of the kinetochore, stabilizing the 
centromere [28]. Through PTEN’s C2 domain, PTEN interacts with CENP-C and without 
PTEN, the Yin lab observed an increase in chromosome aberrations [10]. 
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PTEN in Cell Cycle Regulation: 
It has been known that PTEN is involved in cell cycle regulation due to PTEN deficient 
cells show an arrest in G1 phase [29]. Recently Song et al discovered that PTEN directly 
interacts with the anaphase-promoting complex/cyclosome (APC/C), an E3 ubiquitin 
ligase and its subunit CDH1. This promotes complex stability and has been shown to be 
independent of PTEN’s phosphatase activity [13]. APC/C-CDH1 is active in late mitosis 
and early G1 phase of the cell cycle targeting its substrates, which includes mitotic 
cyclins, Cyclin A and B, and cell cycle kinases Polo-like kinase 1 (PLK1) and Aurora A 
kinase for proteasomal degradation [30, 31]. Cells lacking PTEN result in decreased 
activity of the APC/C-CDH1 complex, leading to prolonged expression of the cell cycle 
kinases previously mentioned and deregulated cell cycle. 
 In addition to PTEN regulating PLK1 protein levels by the stabilization of the 
APC/CDH1 complex, it also has been linked to PLK1 enzymatic regulation through its 
protein phosphatase activity. Zhang et al. have demonstrated that PTEN directly interacts 
with PLK1 and dephosphorylates it on residue T210, inactivating PLK1 kinase activity, 
causing a deregulation of mitosis and chromosome segregation. Interestingly, PLK1 
phosphorylates PTEN on S380, leading to recruitment of PTEN to chromatin and normal 
mitosis progression, indicating a dynamic relationship between these two proteins [32]. 
The Dia lab also established that PTEN phosphorylated on S380 recruits the APC/C 
subunit CDH1 resulting in PTEN polyubiquitination and degradation [33]. PTEN-pS380 
results in appropriate timing of mitotic entrance and exit transitioning into G1 [33].  The 
complex relationship between PTEN, PLK1, and APC/C-CDH1 exposes how important 
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the regulation of PTEN and PLK1 throughout the cell cycle is for normal cell 
progression. 
 
PTEN and the Regulation of DNA Replication 
 PTEN has recently been connected to DNA replication and replication fork 
stability [15-17]. Various check points throughout the cell cycle determine genome 
quality, one occurring in S phase due to DNA lesions forming from faulty replication 
machinery [34, 35]. During their study of a PTEN carboxyl terminal deletion mutant 
found in individuals inflicted with Cowden syndrome, the Yin lab discovered defaults in 
replication [17]. This mutation not only showed that PTEN is important for DNA 
replication but that this function is phosphatase independent. A haplodeficient PTEN+/ΔC 
mouse model where one copy contained a C-terminus truncation was used to determine 
the cause of increased tumor development seen in Cowden syndrome patients [17]. Using 
a comparative genomic hybridization array to analyze genome-wide copy number 
changes, two well-known common fragile site (CFS) genes, Wwox and Fhit, were shown 
to be down regulated. CFSs are regions of DNA that display increased instability under 
replication stress, and fail to complete DNA synthesis [36]. Increased mutations and 
decreased gene expression of the genes at CFSs implies that PTEN is required for 
efficient replication. 
  This finding led the Shen lab to investigate PTEN’s involvement in early S phase 
checkpoint regulation. PTEN null cells exhibit a lower percentage of cells in S phase 
arrest and an accumulation in G2/M arrest. This results in increased chromosome 
aberrations and anaphase bridges preventing chromosome segregation [16]. By dividing 
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S phase into three steps, early (S1), mid (S2), and late (S3), it was shown that, compared 
to wild type cells, PTEN-/- cells have a reduced number of cells at all stages of S phase 
but more prominently in S1 indicating a role for PTEN in early S phase. This phenotype 
was corrected with over expression of RAD51 and CHK1. Using iPOND (isolation of 
proteins on nascent DNA), it was shown that both RAD51, a ssDNA binding protein 
essential for homologous recombination, and CHK1, a cell cycle kinase involved in DNA 
repair, are localized to replication forks [16]. Only loading of RAD51 was affected in 
PTEN-/- cells, while CHK1 replication fork localization remained unaffected. 
Deregulation of RAD51 at DNA lesions leads to inadequate HR repair and increased 
DNA damage. PTEN not only stabilizes RAD51 at stalled replication forks, but also 
stabilizes the single-stranded DNA (ssDNA) binding protein RPA.  Both RAD51 and 
RPA stabilization are independent of PTEN phosphatase activity.  PTEN stabilizes RPA 
by recruiting OTUB1, the deubiquitinase (DUB) of RPA1 at stalled forks [18].  OTUB1 
is a canonical OTU family DUB, targeting K48 linked ubiquitin chains [37, 38]. PTEN 
was shown to form a complex by interacting with RPA1 through its phosphatase domain 
and OTUB1 through its carboxyl terminal, allowing for the deubiquitination of RPA1, 
preventing its proteolytic degradation, and resulting in its stabilization of the RPA 
complex on ssDNA.  
 It was also discovered that PTEN is involved in the stabilization of the replisome 
via its phosphatase domain by dephosphorylating the MCM2 subunit of the MCM 
helicase on residue S41 during replication stress [15]. The MCM helicase contains 6 
subunits MCM2- 7 forming a hexamer to unwind DNA for replication [39]. MCM2 is 
involved in all three stages of DNA replication: initiation, elongation, and termination. 
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DNA replication is a complex process and MCM2 has been shown to be an essential 
regulator of the replisome under stressful conditions, helping to prevent DNA damage. 
[40]. Feng et al. discovered that PTEN associated with MCM2 only under stressful 
replicative conditions, such as treating with the exogenous agent hydroxyurea, a chemical 
that prevents the production of new deoxyribonucleotides and depleting the free 
nucleotide pools [15]. Upon replication stress, PTEN associates with and 
dephosphorylates S41 of MCM2, pausing replication and preventing fork progression in 
order for high fidelity DNA repair to occur by the stabilization of RPA and the 
recruitment of RAD51. 
 
PTEN and its Regulation by Posttranslational Modification: 
Protein posttranslational modification (PTM) is an essential cellular process, which 
regulates complex protein pathways [41, 42]. PTMs signal proteins for localization, 
activation, deactivation, and for protein degradation and cellular compartmentalization 
[41]. PTEN is posttranslationally modified by various small molecules such as phospho 
and acetyl groups or by the addition of small proteins including ubiquitin and 
importantly, SUMO (small ubiquitin-like modifier) for regulation of its many cellular 
activities [8]. It has already been established that PTEN is monoubiquinated for its 
nuclear localization and that phosphorylation of S380 leads to its chromatin stabilization 
and subsequent polyubiquitination and degradation for progression of mitosis. Recently 
the characterization of SUMOylation at residue K254 has been described as crucial for its 
nuclear tumor suppressor function [11]. The addition of SUMO to a target protein occurs 
in multiple biochemical steps. The first is cleavage at the C-terminal of SUMO, exposing 
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the di-glycine motif on the now functional SUMO protein allowing a covalent bond to a 
cysteine on an E1 enzyme, which creates a thioester linkage. The SUMO thioester bond 
can then be transferred to the sole E2 SUMO conjugating enzyme, UBC9, and with the 
help of a RING-domain E3 ligase, the SUMO will then be transferred from the E2 to a 
lysine on the target protein [43, 44]. This process can be repeated to form SUMO chains. 
DeSUMOylating enzymes, SENPs, can reverse this process [45]. 
 Genome stability by DNA repair pathways are tightly regulated by 
posttranslational modification and recently, SUMOylation of many DNA damage 
response (DDR) proteins has been shown to be important for the fluency of DNA repair 
[46]. A DDR protein that has been shown to be SUMOylated is RPA. As previously 
stated, RPA binds and protects ssDNA from nucleolytic degradation. To allow for the 
loading of RAD51 onto the ssDNA creating the nucleofilaments for the essential strand 
invasion step of HR, RPA is polySUMOylated, then polyubiquitinated targeting its 
proteasomal degradation [46].  PTEN is SUMOylated on K254 for its removal from the 
nucleus upon ionizing radiation (IR) damage [11]. Cells expressing the PTEN 
SUMOylation incompetent mutant, K254R, display genome instability and increased 
error-prone repair [11]. PTEN harbors a conserved ATM (ataxia telangiectasia mutated) 
consensus sequence at S398, and when mutated to an alanine, PTEN is no longer able to 
be SUMOylated and subsequently cannot be removed from the nucleus. It has been 
shown that SUMOylation of PTEN is integral to its role in genome stability, but the 
mechanism behind PTEN SUMOylation has yet to be fully understood. PTEN 
SUMOylation could possibly prime PTEN for its polyubiquitination and subsequent 
degradation similar to the regulation of RPA, regulating its nuclear protein levels. 
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Conclusions 
PTEN is one of the most widely mutated genes found in cancer due to its integral roles in 
many cellular processes. Not only is it the antagonist to the PI3K/AKT pro-survival 
pathway, but it also protects the genome at various levels. Here we have summarized how 
PTEN is involved in many stages of the cell cycle and gene regulation by modulation of 
chromatin architecture (Figure 2). Furthermore, PTEN is highly involved in DNA 
replication fork stability. PTEN is not only involved in the restart of stalled replication 
forks by stabilizing RPA and RAD51 for efficient DNA repair, but PTEN also 
dephosphorylates the regulatory subunit of the MCM helicase complex stabilizing the 
replisome and allowing efficient DNA repair and replication restart. Understanding the 
relationship between PTEN and RAD51 allows for new therapies strategies targeting 
cells defective in HR including PARP inhibitors. Further, understanding of how PTEN is 
involved in these cellular processes throughout the cell cycle, such as its relationship with 
PLK1, can establish new treatments targeting the many PTEN deficient tumors. PLK1 is 
over expressed in various tumors and chemical inhibitors against this kinase. For 
example, BI2536, is currently in clinical trials. Determining mechanistically how PTEN 
is involved in DNA replication stability and how specific mutations modify protein 
function can lead to new therapeutic approaches targeting PTEN deficient tumors and 
Cowden syndrome.  
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Figure 2. PTEN’s DNA protection throughout the cell cycle 
1. PTEN involvement in controlling chromatin architecture. First, throughout mitosis, 
PTEN stabilizes centromeres through the direct interaction of the kinetochore subunit 
CENP-C, preventing chromosome aberrations such as translocations. Second, PTEN 
regulates chromatin condensation through its interaction with histone H1 and HP1α 
regulating gene expression.  
2. PTEN and DNA replication fork stability. PTEN stabilizes the replisome when it 
comes in contact with a DNA lesion by dephosphorylating S41 on MCM2, a subunit of 
the MCM helicase. Once the replication fork is stabilized, PTEN recruits RPA’s DUB, 
OTUB1, preventing RPA’s degradation, protecting the ssDNA. PTEN then recruits and 
stabilizes RAD51 to the stalled replication fork, initiating HR. 
3. PTEN and PLK1 relationship and the regulation of mitosis. PTEN regulates the 
activity of PLK1 through mitosis by two independent functions; first by 
dephosphorylation of PLK1 on T210, deactivating the kinase and allowing for efficient 
mitosis and chromosome segregation and second by stabilizing the APC/C-CDH1 E3 ub 
ligase, targeting PLK1 for proteolytic turnover. Interestingly, PLK1 phosphorylates 
PTEN on S380 in late G2, stabilizing PTEN onto chromatin and allowing cell cycle 
progression into M phase. PTEN pS380 signals its chromatin removal and degradation in 
late M phase by recruiting CDH1 and the APC/C complex for entrance into G1. 
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Abstract 
Fanconi anemia (FA) is a genetic disease characterized by bone marrow failure and 
increased cancer risk. The FA proteins function primarily in DNA interstrand crosslink 
(ICL) repair. Here, we have examined the role of the PTEN phosphatase in this process. 
We have established that PTEN-deficient cells, like FA cells, exhibit increased sensitivity 
to ICL cytotoxicity, increased levels of chromosome structural aberrations, and increased 
error-prone mutagenic DNA repair. The increased ICL sensitivity of PTEN-deficient 
cells is caused, in part, by elevated PLK1 kinase-mediated phosphorylation of FANCM, 
constitutive FANCM polyubiquitination and degradation, and the consequent inefficient 
assembly of the FA core complex, FANCD2, and FANCI into DNA repair foci. We also 
establish that PTEN function in ICL repair is dependent on its protein phosphatase 
activity, yet independent of its lipid phosphatase activity. Finally, via epistasis analysis, 
we demonstrate that PTEN and FANCD2 function cooperatively in ICL repair.  
 
Introduction 
Fanconi anemia (FA) is a rare autosomal and X-linked disease characterized by 
congenital abnormalities, progressive pediatric bone marrow failure, and increased cancer 
risk in early adulthood1. FA is caused by mutation of any one of 21 genes (FANCA, -B, -
C, -D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, -O/RAD51C, -P/SLX4, -
Q/ERCC4, -R/RAD51, -S/BRCA1, -T/UBE2T, -U/XRCC2 and -V/REV7). The FA proteins 
function in the FA-BRCA pathway to facilitate the removal of DNA interstrand 
crosslinks (ICLs) and to maintain genome stability2-4. ICLs are highly toxic lesions that 
covalently link DNA strands, imposing a direct physical block to DNA replication and 
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transcription. The FA-BRCA pathway resolves ICLs by first converting these lesions into 
DNA double-strand breaks (DSBs)5. The DSB is then repaired by homologous 
recombination (HR), a conservative DNA repair mechanism that uses the homologous 
DNA sequence on a sister chromatid or homologous chromosome as a template to copy 
and repair the damaged DNA. The RAD51 protein is the major cellular HR protein and 
catalyzes the critical strand invasion step of HR6,7. 
  Eight FA proteins, as well as several accessory proteins, form the FA core 
complex, a multisubunit E3 ubiquitin ligase that catalyzes the monoubiquitination of the 
FANCD2 and FANCI proteins2,8. FANCD2/I monoubiquitination is an essential step in 
the activation of the FA-BRCA pathway8,9. Monoubiquitinated FANCD2 co-localizes in 
discrete chromatin-associated nuclear foci with several DNA repair proteins, including 
RAD51/FANCR and BRCA2/FANCD110,11. FANCD2 and BRCA2/FANCD1 function 
together to promote RAD51/FANCR nucleoprotein filament formation and DNA strand 
exchange during HR10,12,13. 
In addition to being regulated by ubiquitination, the FA-BRCA pathway is also 
extensively regulated via phosphorylation. For example, FANCD2 and FANCI are 
phosphorylated by the two major DNA damage response kinases ATM (ataxia 
telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related)14-17. FANCI 
phosphorylation on six clustered SQ/TQ motifs is required for its monoubiquitination and 
nuclear foci formation16. In addition, FANCM is hyperphosphorylated by PLK1 during 
mitosis, promoting its ubiquitination and degradation by the proteasome18. Importantly, 
to date, no phosphatases have been directly linked to the FA-BRCA pathway.  
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 PTEN encodes a dual specificity phosphatase capable of removing phosphates 
from both proteins and lipids19,20. The principal catalytic function of PTEN is to dephos-
phorylate the lipid second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), a 
potent activator of the AKT kinases20. As a consequence, loss of PTEN catalytic function 
leads to de-repression of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and 
stimulation of cell growth and survival pathways21,22. While this plasma membrane 
localized PTEN function is central to tumor suppression, recent studies have established 
that PTEN has PI3K/AKT-independent nuclear tumor suppressive functions23,24. Indeed, 
important roles for PTEN in the regulation of cell cycle progression and the maintenance 
of chromosome stability have recently been established25-28. 
 In this study, we have investigated the role of PTEN in ICL repair and in the 
regulation of the FA-BRCA pathway. We have established that PTEN plays an important 
role in ICL repair as PTEN-deficient cells, like FA patient cells, exhibit increased 
sensitivity to ICL-mediated cytotoxicity, and display increased levels of chromosome 
structural aberrations following ICL exposure. The increased ICL sensitivity of PTEN-
deficient cells is caused, in part, by elevated PLK1 kinase-mediated phosphorylation of 
FANCM, constitutive FANCM polyubiquitination and degradation, and the consequent 
inefficient assembly of the FA core complex, FANCD2, and FANCI into DNA repair 
foci. We also show that PTEN function in ICL repair is independent of its lipid 
phosphatase activity yet dependent on its protein phosphatase activity. We also establish 
that PTEN deficiency leads to increased mutagenic ICL repair, exemplified by increased 
53BP1 and DNA-PKcs-pS2056 nuclear foci formation, biomarkers of the error-prone 
nonhomologous DNA end joining (NHEJ) repair pathway. Finally, using an RNA 
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interference approach in FA-D2 patient cells and PTEN-deficient tumor lines, we 
demonstrate that PTEN and FANCD2 function epistatically during ICL repair. Our 
results uncover important mechanistic insight into the role of nuclear PTEN in ICL repair 
and establish the convergence of two critical tumor suppressor pathways.  
 
Results 
PTEN is required for chromosome stability and cellular survival following 
mitomycin C treatment 
To investigate the role of PTEN in ICL repair we treated isogenic HCT116 PTEN+/+ and 
PTEN-/- cells with mitomycin C (MMC) and examined cellular cytotoxicity and 
metaphase chromosome aberrations. Similar to FA patient cells that are characteristically 
sensitive to ICL-inducing agents29,30 two independently derived PTEN-/- lines exhibited 
increased sensitivity to MMC. The calculated LD50 values for PTEN+/+ cells were 2-fold 
greater than those for both PTEN-/- lines (Figure S1A). PTEN-/- cells also exhibited 
increased spontaneous and MMC-inducible chromosome gaps and breaks and complex 
aberrations, including radial formations (Figures 1A-C). For example, we observed a ~4-
fold increase (P < 0.05) in spontaneous gaps and breaks in PTEN-/- #22 cells compared 
with PTEN+/+ cells (Figure 1B). Importantly, the chromosome instability phenotype of 
PTEN-/- cells could be rescued by re-expression of wild-type PTEN (see Figure 6). We 
next examined the role of PTEN in ICL repair in a non-transformed cell model using the 
isogenic mammary epithelial cells MCF10A PTEN+/+ and PTEN-/-. Again PTEN-/- cells 
exhibited increased sensitivity to the cytotoxic effects of MMC (Figure S1B). We also 
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Figure 1. PTEN-/- cells are hypersensitive to the clastogenic effects of mitomycin C   
HCT116 and MCF10A PTEN+/+ and PTEN-/- cells were incubated in the absence or 
presence of mitomycin C (MMC) for 24 h and metaphase spreads were analyzed for 
numerical and structural chromosome aberrations.  
(A) Representative images of the types of chromosome aberrations - including radial 
formations, telomere fusions, dicentrics, and complex aberrations - observed in PTEN-/- 
cells following MMC treatment.  
(B and C) Quantification of chromosome gaps and breaks (B) and total chromosome 
aberrations (C) observed in HCT116 PTEN+/+ and two independent clones of PTEN-/- 
cells incubated in the absence or presence of 20 nM MMC for 24 h. 
(D and E) Quantification of chromosome gaps and breaks (D) and total chromosome 
aberrations (E) observed in MCF10A PTEN+/+ and PTEN-/- cells incubated in the absence 
or presence of 24 nM MMC for 24 h. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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observed an increased frequency of both spontaneous and MMC-inducible chromosome 
gaps and breaks and complex aberrations in the MCF10A PTEN-/- cells compared to 
PTEN+/+ cells (Figures 1A and D). A ~4-fold (P < 0.001) increase in spontaneous 
complex chromosome aberrations and a ~2-fold (P < 0.05) increase in MMC-inducible 
complex aberrations were observed for MCF10A PTEN-/- cells, compared to PTEN+/+ 
cells (Figures 1A and E). MCF10A PTEN-/- cells also exhibited a striking increase in 
both spontaneous and ICL-inducible centromere aberrations, exemplified by de-
condensed centromeres, similar to that previously described27 (Figures S1C and D).  
 
PTEN is required for efficient MMC-inducible FANCD2 and FANCI nuclear foci 
formation 
To gain insight into the molecular basis of the increased ICL sensitivity of PTEN-
deficient cells, we examined the activation of the FA-BRCA pathway in these cells, a 
pathway known to play a critical role in the cellular ICL response3. Activation of this 
pathway occurs via the site-specific monoubiquitination of the FANCD2 and FANCI 
proteins and their assembly into discrete nuclear foci9,31,32. HCT116 PTEN+/+ and PTEN-/- 
cells were treated with MMC for 16 h followed by a 24 h recovery period. Following 
MMC treatment, PTEN+/+ cells exhibited a strong increase in FANCD2 and FANCI 
nuclear foci formation with ~60% of cells displaying greater than 5 discrete nuclear foci 
(Figures 2A and B). In contrast, no appreciable induction of FANCD2 or FANCI 
nuclear foci formation was observed for PTEN-/- cells following MMC exposure (Figures 
2A and B). Re-expression of PTEN in PTEN-/- cells restored efficient MMC-inducible 
FANCD2 or FANCI nuclear foci formation (see Figures 6C and D). No overt 
differences in MMC-inducible FANCD2 or FANCI monoubiquitination were observed 
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Figure 2. PTEN is required for efficient mitomycin C-inducible FANCD2 and 
FANCI nuclear foci formation  
(A) HCT116 PTEN+/+ and PTEN-/- cells were incubated in the absence or presence of 40 
nM mitomycin C (MMC) for 18 h and FANCD2 and FANCI nuclear foci formation were 
analyzed by immunofluorescence microscopy. Representative images of FANCD2 and 
FANCI nuclear foci from cells exposed to MMC are shown. 
(B) Quantification of the percentage of PTEN+/+ and PTEN-/- nuclei displaying greater 
than five discrete FANCD2 or FANCI nuclear foci. Cells were incubated in the absence 
(NT) or presence of 40 nM MMC for 18 h and allowed to recover for up to 24 h. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
(C) Immunoblotting for FANCD2, FANCI, and RAD51 reveals no appreciable 
differences in levels of MMC-inducible FANCD2 and FANCI monoubiquitination or 
RAD51 between PTEN+/+ and PTEN-/- cells. Cells were incubated in the absence or 
presence of 200 nM MMC for 24 h and allowed to recover for up to 24 h. α-Tubulin was 
used as a loading control. To improve clarity and conciseness, the presented blots have 
been cropped. All gels were run under the same experimental conditions. 
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between PTEN+/+ and PTEN-/- cells (Figure 2C). Furthermore, using a cellular 
fractionation approach, we did not observe appreciable differences in the chromatin 
enrichment of FANCD2 or FANCI in the absence of PTEN (Figure S2A). Very similar 
results were obtained with MCF10A PTEN-/- cells, which exhibited markedly reduced 
levels of MMC-inducible FANCD2 and FANCI nuclear foci, compared with PTEN+/+ 
cells (Figures S2B and C), but no discernible differences in MMC-inducible FANCD2 
or FANCI monoubiquitination or chromatin enrichment (Figures S2D and E).  
 
Increased FANCM instability and defective chromatin recruitment of the FA core 
complex in PTEN-deficient cells  
Previous studies have established that the FANCM protein is required for efficient 
recruitment of the FA core complex to chromatin and for the assembly of FANCD2 and 
FANCI nuclear foci33,34. Therefore we examined FANCM expression in PTEN+/+ and 
PTEN-/- cells. In the absence of PTEN, we observed reduced levels of FANCM (Figures 
S3A and B). Modest reductions in total cellular levels of FANCA were also observed 
(Figures S3A and B). A cycloheximide pulse-chase experiment revealed that reduced 
FANCM levels were a consequence of increased FANCM turnover: increased FANCM 
instability could be rescued by inhibition of the proteasome with MG132 (Figures 3A 
and S3C). p53 was used a positive control for these experiments because of its fast 
proteolytic turnover. Furthermore, we observed reduced chromatin-associated FANCM 
and ICL-inducible FANCM nuclear foci formation in the absence of PTEN (Figures 3B, 
3C, S3D, and S3G). Consistent with an important role for FANCM in promoting the 
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Figure 3. Increased FANCM instability and defective chromatin recruitment of the 
FA core complex in PTEN-deficient cells  
(A) HCT116 PTEN+/+ and PTEN-/- cells were incubated in the absence or presence of 40 
µg/mL cycloheximide (CHX) alone or 40 µg/mL CHX and 4 µM MG132 (CHX + MG) 
for the indicated times. Whole-cell lysates were prepared and immunoblotted with anti-
FANCM, anti-p53, and anti-PTEN antibodies. RBI, Relative protein band intensity. 
(B) Chromatin fractionation analysis of MCF10A PTEN+/+ and PTEN-/- cells reveals a 
defect in the chromatin localization of FANCM and FANCA in the absence of PTEN. 
Cells were incubated in the absence (NT) or presence of 200 nM mitomycin C (MMC) 
for 24 h. W, unfractionated whole-cell lysate; S, soluble cytoplasmic and nuclear 
fraction; C, chromatin fraction. For (A) and (B), to improve clarity and conciseness, the 
presented blots have been cropped. All gels were run under the same experimental 
conditions. C:S, Ratio of protein in the chromatin versus soluble fraction.  
(C) Quantification of FANCM nuclear foci formation in MCF10A PTEN+/+ and PTEN-/- 
cells reveals a defect in MMC-inducible FANCM nuclear foci formation in PTEN-/- cells. 
Cells were incubated in the absence (NT) or presence of 200 nM MMC for 18 h. ***, P < 
0.001. 
(D) Quantification of FANCA nuclear foci formation in MCF10A PTEN+/+ and PTEN-/- 
cells reveals reduced FANCA nuclear foci formation in PTEN-/- cells both in the absence 
(NT) and presence of MMC. Cells were treated as described for (C). ***, P < 0.00
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chromatin localization of the FA core complex, we also observed defective ICL-inducible 
FANCA chromatin localization and nuclear foci formation in PTEN-/- cells (Figures 3B, 
3D, S3E, S3F, and S3H). 
 
Inhibition of PLK1 rescues defective FANCD2 nuclear foci formation but is not 
sufficient to rescue the chromosome instability of PTEN-/- cells  
Previous studies have established that nuclear PTEN stabilizes the APC/C (anaphase-
promoting complex/cyclosome) E3 ubiquitin ligase complex and, in the absence of 
PTEN, there is an increase in the activity of APC/C substrates as they escape ubiquitin-
mediated proteolysis28. One such APC/C target is the PLK1 mitotic kinase28. PLK1 
phosphorylates FANCM, a FA core complex member, and primes it for 
polyubiquitination and degradation during mitosis18. To determine if increased PLK1 
activity contributes to the increased FANCM instability observed in PTEN-/- cells, we 
incubated cells in the absence and presence of MMC and the small molecule PLK1 
inhibitor BI253635,36. We observed a marked stabilization of FANCM in both PTEN+/+ 
and PTEN-/- cells following BI2536 treatment, stabilization being more pronounced in 
PTEN-/- cells (Figure 4A). Furthermore, higher molecular weight FANCM isoforms, 
which are consistently more evident in PTEN-/- cells (Figures 4A and B, compare lanes 
1 and 5), become reduced upon BI2536 treatment (Figure 4A). A λ-phosphatase assay 
indicates that these higher molecular weight FANCM isoforms most likely represent both 
phosphorylated and polyubiquitinated FANCM, consistent with previous findings18, and 
that FANCM is particularly unstable in PTEN-/- cells following MMC exposure (Figure 
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Figure 4. Inhibition of PLK1 rescues defective FANCD2 nuclear foci formation but 
is not sufficient to rescue the chromosome instability of PTEN-/- cells  
(A) HCT116 PTEN+/+ and PTEN-/- cells were incubated in the absence (-) and presence 
(+) of 100 nM BI2536 and 500 nM mitomycin C (MMC) for 18 h, and whole-cell lysates 
were immunoblotted with the indicated antibodies. L:S, Ratio of phosphorylated to 
unphosphorylated FANCM. 
(B) PTEN+/+ and PTEN-/- cells were incubated in the absence and presence of 200 nM 
MMC for 24 h. Whole-cell lysates were then incubated in the absence (-) or presence (+) 
of 10 U/µg λ-phosphatase for 4 h at 30 °C, followed by immunoblotting with the 
indicated antibodies. For (A) and (B), to improve clarity and conciseness, the presented 
blots have been cropped. All gels were run under the same experimental conditions. RBI, 
Relative unmodified FANCM protein band intensity.  
(C) PTEN+/+ and PTEN-/- cells were incubated in the absence or presence of 2 nM 
BI2536, 20 nM MMC, or both BI2536 and MMC for 24 h and metaphase spreads were 
analyzed for the presence of numerical and structural chromosome aberrations.  
(D) PTEN-/- cells stably expressing empty vector or wild-type PTEN were incubated in 
the absence or presence of 5 nM BI2536, 200 nM MMC, or both BI2536 and MMC for 
24 h, and allowed to recover for 8 h, and FANCD2 nuclear foci formation were analyzed 
by immunofluorescence microscopy. ***, P < 0.001, in comparison to cells incubated 
without B12536.  
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4B). To determine if PLK1 inhibition could rescue the ICL sensitivity of PTEN-/- cells, 
we co-treated cells with MMC and BI2536 and examined metaphase spreads for 
chromosome aberrations. While BI2536 treatment resulted in a slight reduction in levels 
of ICL-inducible chromosome aberrations in PTEN-/- cells, this decrease was not 
statistically significant at the concentrations tested (Figure 4C). Higher concentrations of 
BI2536 lead to M-phase arrest precluding metaphase chromosome analyses. BI2536-
mediated PLK1 inhibition did, however, rescue the defective MMC-inducible FANCD2 
nuclear foci formation in PTEN-/- cells expressing empty vector (Figure 4D). 
Importantly, 8 h following exposure to MMC and BI2536, while the percentage of 
PTEN+/+ nuclei exhibiting FANCD2 nuclear foci had returned to pre-exposure levels, 
FANCD2 nuclear foci persisted in PTEN-/- cells (Figure 4D). As increased FANCM 
phosphorylation in PTEN-/- cells could be a consequence of increased PLK1 kinase 
activity or decreased PTEN phosphatase activity, we performed an in vitro kinase and 
phosphatase assay with purified FANCM, PLK1, and PTEN. While we observed robust 
PLK1-mediated FANCM phosphorylation, under the conditions tested,  
we did not observe any appreciable decrease in levels of phosphorylated FANCM upon 
incubation with PTEN (Figure S4). Taken together, these results indicate that, in the 
absence of PTEN, elevated PLK1 activity contributes to increased FANCM proteolysis 
leading to inefficient chromatin recruitment of the FA core complex and attenuated 
FANCD2 nuclear foci formation.  
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Figure 5. Increased γH2AX, 53BP1, and DNA-PKcs pS2056 nuclear foci formation 
in PTEN-deficient cells 
(A) Quantification of γH2AX nuclear foci formation in HCT116 PTEN+/+ and PTEN-/- 
cells reveals persistent elevated levels of γH2AX nuclear foci in PTEN-/- cells following 
mitomycin C (MMC) treatment. Cells were incubated in the absence (NT) or presence of 
40 nM MMC for 18 h and allowed to recover for up to 24 h. ***, P < 0.001. 
(B) Quantification of 53BP1 nuclear foci formation in PTEN+/+ and PTEN-/- cells reveals 
persistently elevated levels of 53BP1 nuclear foci in PTEN-/- cells following MMC 
treatment. Cells were treated as described for (A). 
(C) Quantification of DNA-PKcs pS2056 nuclear foci formation in PTEN+/+ and PTEN-/- 
cells reveals persistently elevated levels of DNA-PKcs pS2056 nuclear foci in PTEN-/- 
cells. Cells were treated as described for (A and B).  
(D) Quantification of FK2 nuclear foci formation reveals no overt differences in levels of 
mono-, multi-, or poly-ubiquitin conjugates between PTEN+/+ and PTEN-/- cells. Cells 
were treated as described for (A-C).  *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Increased γH2AX, 53BP1 and DNA-PKcs pS2056 nuclear foci formation in PTEN-
deficient cells To gain further insight into the underlying mechanisms of chromosome 
instability in PTEN-deficient cells, we next examined the levels of several DNA damage 
response biomarkers in PTEN+/+ and PTEN-/- cells using immunofluorescence 
microscopy. Cells were treated with MMC for one cell cycle and allowed to recover for 
up to 24 h following exposure. We observed a large increase in γH2AX nuclear foci 
formation in both PTEN+/+ and PTEN-/- cells following MMC exposure (Figure 5A). 
Following 24 h recovery, the percentage of PTEN+/+ nuclei exhibiting γH2AX nuclear 
foci had returned to pre-exposure levels. However, in contrast, γH2AX nuclear foci 
persisted in PTEN-/- nuclei at this time point (Figure 5A). We also observed a large 
increase in 53BP1 nuclear foci formation in both PTEN+/+ and PTEN-/- cells following 
MMC exposure (Figure 5B). However, persistently elevated levels of PTEN-/- nuclei 
staining positive for 53BP1 nuclear foci formation were observed for up to 24 h 
following MMC treatment (Figure 5B). Similar findings of increased and/or persistent 
γH2AX and 53BP1 nuclear foci were observed for MCF10A PTEN-/- cells (Figures S5A 
and B). We also observed increased levels of chromatin-associated 53BP1 in PTEN-/- 
cells in the absence and presence of MMC (Figure S5C). Next we examined DNA-PKcs 
pS2056 nuclear foci formation, a biomarker of NHEJ37,38, in PTEN+/+ and PTEN-/- cells. 
Similar to γH2AX and 53BP1, persistently elevated levels of DNA-PKcs pS2056 nuclear 
foci formation were observed in PTEN-/- nuclei at all time points following MMC 
treatment (Figure 5C). In contrast, no differences in overall levels of mono-, multi-, or 
poly-ubiquitin conjugates between PTEN+/+ and PTEN-/- cells were observed (Figure 
5D). Collectively, these results strongly suggest that PTEN-deficient cells have a defect 
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in efficient DSB repair, possibly as a consequence of aberrant DSB end processing, and 
preferentially use mutagenic DSB repair pathways such as NHEJ. Notably, we did not 
observe any significant differences in levels of RAD51 protein expression (Figures 2C 
and S2D), chromatin enrichment (Figures S2A and E), or nuclear foci formation 
(Figures S5D and E), between PTEN+/+ and PTEN-/- cells for both HCT116 and 
MCF10A cell models.   
 
PTEN function in ICL repair is protein phosphatase dependent 
To gain further mechanistic insight into the role of PTEN in ICL repair, we 
complemented HCT116 PTEN-/- cells with wild type PTEN, lipid phosphatase-defective 
PTEN-G129E, and lipid and protein phosphatase-defective PTEN-C124S 19,25,39. The 
PTEN variants behaved as predicted with only wild type able to down-regulate the 
PI3K/AKT pathway, as demonstrated by loss of AKT-pS473 signal (Figure 6A). We 
exposed these cells to MMC and analyzed metaphase chromosomes for the presence of 
gaps, breaks, and radial formations. Both wild type PTEN and the PTEN-G129E mutant 
rescued the sensitivity of PTEN-/- cells to MMC-induced chromosome damage. However, 
expression of the PTEN-C124S failed to rescue the ICL sensitivity of PTEN-/- cells 
(Figure 6B). Cells stably expressing PTEN-C124S exhibited increased chromosome gaps 
and breaks and radial formations compared with cells expressing wild-type PTEN, 
following exposure to MMC (P < 0.001) (Figure 6B). Furthermore, analysis of FANCD2 
and FANCI nuclear foci formation in these cells revealed inefficient MMC-inducible 
FANCD2 and FANCI nuclear foci formation in PTEN-/- cells stably expressing PTEN-
C124S, similar to cells expressing LacZ (Figures 6C and D). To further confirm the 
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Figure 6. PTEN function in ICL repair is protein phosphatase dependent 
(A) HCT116 PTEN-/- cells were stably transduced with pLenti6.2-LacZ, -PTEN-WT, -
PTEN-C124S, and -PTEN-G129E. Whole-cell lysates were prepared and immunoblotted 
for PTEN, AKT, AKT pS473, RAD51, and α-tubulin. To improve clarity and 
conciseness, the presented blots have been cropped. All gels were run under the same 
experimental conditions. 
(B) PTEN-C124S fail to rescue the sensitivity of PTEN-/- cells to the clastogenic effects 
of mitomycin C (MMC), in contrast to PTEN-WT or PTEN-G129E. Cells were incubated 
in the absence (NT) or presence of 20 nM MMC for 24 h and metaphase spreads were 
analyzed for structural chromosome aberrations. ***, P < 0.001. 
(C and D) Defective FANCD2 (C) and FANCI (D) nuclear foci formation in PTEN-/- 
cells expressing LacZ, and PTEN-C124S. Cells were incubated in the absence (NT) or 
presence of 200 nM MMC for 18 h. ***, P < 0.001. 
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requirement for PTEN protein (but not lipid) phosphatase activity, we also show that 
PTEN-/- cells stably expressing PTEN-Y138L are ICL sensitive and fail to properly form 
FANCD2 and FANCI nuclear foci formation (Figures S6A-D). This missense mutation 
was previously shown to abrogate PTEN protein phosphatase activity but not lipid 
phosphatase activity40. Moreover, while wild type PTEN and the PTEN-G129E mutant 
rescued defective ICL-inducible FANCA and FANCM nuclear foci formation, the 
PTEN-C124S, and Y138L mutants did not (Figures S6E and F). Taken together, these 
results establish that PTEN functions in the activation of the FA pathway, and ICL repair 
is lipid phosphatase-independent. 
 
PTEN and FANCD2 epistasis analysis  
To determine if PTEN functions epistatically with the FA proteins in ICL repair, we used 
an RNA interference approach to deplete PTEN in FA-D2 (FANCD2-/-) patient-derived 
cells stably expressing empty vector or pLenti6.2-FANCD2 (FA-D2 + FANCD2), and 
examined their response to MMC. Increased levels of AKT S473 phosphorylation 
confirmed the functional depletion of PTEN in FA-D2 and FA-D2 + FANCD2 cells 
(Figure 7A). Consistent with our earlier findings demonstrating an important role for 
PTEN in ICL repair, depletion of PTEN in FA-D2 + FANCD2 cells resulted in increased 
sensitivity to the cytotoxic effects of MMC (Figure 7B). However, no differences in 
sensitivity to MMC cytotoxicity were observed between FA-D2 cells transfected with 
control non-targeting siRNA or PTEN siRNA, or FA-D2 + FANCD2 cells transfected 
with PTEN siRNA (Figure 7B). Similarly, depletion of PTEN in FA-D2 cells did not 
lead to a further increase in the numbers of chromosome gaps, breaks or complex  
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Figure 7. PTEN functions epistatically with FANCD2 in ICL repair  
(A) siRNA-mediated knockdown of PTEN in FA-D2 (FANCD2-/-) and FA-D2 + 
FANCD2 cells. Increased levels of AKT S473 phosphorylation confirmed the functional 
depletion of PTEN. To improve clarity and conciseness, the presented blots have been 
cropped. All gels were run under the same experimental conditions. 
(B) Knockdown of PTEN (siPTEN) in FA-D2 + FANCD2 cells leads to increased 
sensitivity to mitomycin C (MMC) cytotoxicity. In contrast, knockdown of PTEN in FA-
D2 (FANCD2-/-) cells does not lead to a further increase in sensitivity to MMC 
cytotoxicity. siCtrl, non-targeting siRNA.  
(C and D) Metaphase chromosome analysis of FA-D2 (FANCD2-/-) cells reveals that 
knockdown of PTEN does not lead to a further increase in the levels of chromosome gaps 
and breaks (C) or total chromosome aberrations (D), including radial formations, 
dicentrics, and complex aberrations.  
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aberrations (Figures 7C, D and S7A). We also performed the reciprocal analyses 
whereby we knocked down FANCD2 in the PTEN-deficient prostate carcinoma cell line 
PC-3 again using siRNA (Figure S7B). No increase in MMC-sensitivity was observed 
upon knockdown of FANCD2 in PC-3 cells (Figure S7C). Similarly, depletion of 
FANCD2 in PC-3 cells did not lead to an increase in chromosome gaps, breaks or 
complex aberrations (Figures S7D-F). Collectively, these results strongly suggest that 
FANCD2 and PTEN function epistatically in the cellular ICL response.  
 
Discussion  
PTEN is one of the most widely mutated genes in cancer41-43. While a major tumor 
suppressive function of PTEN is the regulation of PI3K/AKT signaling, several recent 
studies have indicated an additional and important PI3K/AKT-independent function for 
PTEN in the maintenance of chromosome stability25,27,44. However, this function remains 
poorly defined. Here, we have expanded our understanding of the function and regulation 
of PTEN in the maintenance of chromosome stability by specifically analyzing the role of 
PTEN in ICL repair. We demonstrate that cells lacking PTEN are phenotypically similar 
to cells from FA patients and exhibit increased ICL-sensitivity. We also establish a novel 
requirement for PTEN in the activation of the FA-BRCA pathway: PTEN is necessary for 
efficient ICL-inducible FANCD2 and FANCI nuclear foci formation. In contrast, ICL-
inducible FANCD2 and FANCI monoubiquitination and chromatin enrichment are intact 
in the absence of PTEN. The uncoupling of monoubiquitination and chromatin 
enrichment from nuclear foci formation and effective ICL repair has previously been 
observed: Usp1-/- murine embryonic fibroblasts display elevated levels of 
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monoubiquitinated Fancd2 and Fancd2 chromatin localization, but fail to support Fancd2 
nuclear foci formation, and exhibit ICL-hypersensitivity45. Similarly, Fancm or 
Fancs/Brca1 knockout mouse cells show Fanci and Fancd2 monoubiquitination after high 
doses of DNA damage, but do not properly localize these proteins into DNA damage 
foci46,47. These findings emphasize that the assembly of FANCD2 and FANCI into 
nuclear foci is critical for efficient ICL repair. It is highly likely that the targeting of 
FANCD2 and FANCI to specific genomic loci, for example actively transcribed regions 
where co-transcriptional RNA-DNA hybrids (R-loops) arise, is essential for the 
promotion of efficient ICL repair48,49. Indeed, ongoing studies in our laboratory indicate 
that targeting to specific histone methyl marksis key for the assembly of FANCD2 and 
FANCI nuclear foci and efficient ICL repair (Paquin, K.L. and Howlett, N.G., 
unpublished findings). 
 Here, we also provide novel mechanistic insight into the role of PTEN in the 
promotion of efficient ICL repair (Figure S8). We establish a requirement for PTEN 
protein phosphatase activity, but not its lipid phosphatase activity, in ICL repair. PTEN 
has recently been shown to dephosphorylate MCM2 S41 and PLK1 T21050,51, and both of 
these mechanisms are likely to contribute to the observed phenotypes of PTEN-/- cells. 
Dephosphorylation of MCM2 S41 prevents replication fork progression under conditions 
of replication stress50. ICLs are well known to pose a potent block to replication fork 
progression52. PLK1 T210 dephosphorylation leads to its deactivation and 
destabilization51. As PLK1 phosphorylates FANCM during mitosis and promotes its 
polyubiquitination and degradation by the proteasome18, a failure to deactivate PLK1 
results in constitutive FANCM polyubiquitination and degradation. Nuclear PTEN has 
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also been shown to promote the assembly of the APC/C-CDH1 ubiquitin ligase 
complex28. In the absence of PTEN, APC/C-CDH1 substrates, such as PLK1 and Aurora 
A kinase escape ubiquitin-mediated proteolysis and remain active28. In our study, we 
demonstrate that FANCM protein instability and FANCD2 nuclear foci formation can be 
rescued by inhibition of the proteasome and PLK1, respectively, supporting a model 
whereby, in the absence of PTEN, constitutive PLK1 activity leads to constitutive 
FANCM polyubiquitination and degradation, precluding efficient activation of the FA 
pathway. It is also important to note that the relationship between PTEN and PLK1 is 
complex; in addition to PTEN dephosphorylating PLK151 and promoting the assembly of 
the APC/C-CDH1 complex28, PLK1 directly phosphorylates PTEN on S380 promoting 
its accumulation in chromatin53.     
Finally, using FA-D2 patient cells, PTEN-deficient tumor lines, and siRNA 
targeting FANCD2 and PTEN, we have also established that PTEN and FANCD2 
function largely epistatically during the process of ICL repair, as the combined loss of 
both proteins conferred no greater sensitivity to the cytotoxic or clastogenic effects of 
MMC. These findings are consistent with PTEN functioning upstream of FANCD2 and 
FANCI activation as discussed. Similar to FA patient cells, we have also established that 
error-prone DNA repair pathways are preferentially activated in the absence of 
PTEN37,61. PTEN-deficient cells display elevated and persistent levels of 53BP1 and 
DNA-PKcs pS2056 nuclear foci following ICL exposure, indicative of increased usage of 
the typically mutagenic NHEJ DNA repair pathway. Persistent 53BP1 nuclear foci have 
also been observed in PTEN-/- cells exposed to ionizing radiation25. The defect in the 
timely dissolution of γH2AX nuclear foci formation and the increased incidence of 
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chromosome structural aberrations in PTEN-/- cells observed in our study are also 
indicative of an increased reliance on NHEJ. The reasons for NHEJ bias in FA and 
PTEN-deficient cells remain to be determined. A previous study had established that 
PTEN and the E2F-1 transcription factor cooperate to regulate the transcription of 
RAD5127. As DSBs can be repaired via HR or NHEJ, the increased NHEJ bias in PTEN-
deficient cells may be a direct consequence of compromised HR due to reduced RAD51 
protein levels27. However, consistent with the findings of others 62, we did not observe 
appreciable differences in RAD51 expression, chromatin enrichment, or nuclear foci 
formation between PTEN+/+ and PTEN-/- cells. Elegant studies on ICL repair using 
Xenopus egg extracts have recently established that RAD51 ICL binding occurs upstream 
of DSB formation and is not affected by the absence of FANCD2 or FANCI, indicating 
that they are most likely not required for RAD51 chromatin loading63. FANCD2 is, 
however, necessary for the dual incisions flanking the ICL that occur prior to DSB 
formation64. In the absence of PTEN, inefficient FANCD2 and FANCI nuclear foci 
formation most likely leads to a failure to generate these incisions resulting in the 
subversion of repair from error-free HR to error-prone NHEJ. Accordingly, several 
studies have established an important role for PTEN in HR25,65. As HR-deficient tumors 
are hypersensitive to inhibitors of poly (ADP-ribose)-polymerase-1 (PARP) 66,67, our 
studies, and those of others, continue to raise the prospect of tailored combination chemo- 
and radiation therapeutic approaches for PTEN-deficient tumors.    
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Materials and Methods 
Cell culture  
HCT116 PTEN+/+, PTEN-/- #22, and PTEN-/- #3568 (a kind gift from Todd Waldman, 
Lombardi Cancer Center, Georgetown University) were grown in McCoy’s medium 
supplemented with 12% v/v FBS, 1% v/v L-glutamine, and 1% v/v 
penicillin/streptomycin. Stably complemented HCT116 lines were generated by 
transduction with pLenti6.2/V5-DEST (Invitrogen) lentivirus harboring wild type or 
mutant PTEN cDNAs. Stable cell lines were grown in McCoy’s medium supplemented 
with 5 µg/ml blasticidin.  FA-D2 (FANCD2hy/-) cells were purchased from Coriell Cell 
Repositories (Catalog ID GM16633)69. Corrected FA-D2 cells were generated by 
transduction with pLenti6.2-FANCD2 lentivirus, followed by selection in DMEM 
supplemented with 15% v/v FBS, 1% v/v L-glutamine, 1% v/v penicillin/streptomycin 
and 2 µg/ml blasticidin. The PC-3 prostate adenocarcinoma line (a kind gift from David 
Mills, Department of Medicine, Brown University) was grown in DMEM supplemented 
with 12% v/v FBS, 1% v/v L-glutamine, and 1% v/v penicillin/streptomycin. MCF10A 
PTEN+/+ and PTEN-/- cells (Horizon Discovery, U.K.) were grown in DMEM F12 
supplemented with 5% v/v horse serum, 20 ng/ml epidermal growth factor, 0.5 mg/ml 
hydrocortisone, 100 ng/ml cholera toxin, 10 µg/ml insulin, 1% v/v L-glutamine, and 1% 
v/v penicillin/streptomycin. Detailed descriptions of plasmids, site-directed mutagenesis, 
siRNA transfections, and chromosome breakage, cytotoxicity, and cell proliferation 
assays are included in the Supplemental Experimental Procedures. 
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Immunoblotting and antibodies 
For immunoblotting analysis, cell suspensions were washed in ice-cold PBS and lysed in 
50 mM Tris.Cl pH 7.4, 1.0% v/v NP-40, 0.25% w/v Deoxycholic acid, 150 mM NaCl, 1 
mM EGTA, 1 mM PMSF, 1 mM Na3O4V, 1 mM NaF, plus protease inhibitors cocktail 
(Roche). The cellular fractionation method is described in the Supplemental 
Experimental Procedures. Proteins were resolved on NuPAGE 3-8% w/v Tris-Acetate or 
4–12% w/v Bis-Tris gels (Invitrogen) and transferred to polyvinylidene difluoride 
(PVDF) membranes. The following antibodies were used: rabbit polyclonal anti-53BP1 
(sc-22760; Santa Cruz Biotechnology), anti-FANCA (ABP6201; Cascade), anti-
FANCD2 (NB100-182; Novus Biologicals), anti-FANCI (Dr. Patrick Sung, Yale 
University and A301-254A; Bethyl Laboratories), anti-FANCM (a kind gift from Dr. 
Ruhikanta Meetei, Cincinnati Children’s Hospital), anti-FANCM (3821; Fanconi Anemia 
Research Fund), anti-H2A (07-146; Millipore), and anti-PTEN (9559;Cell Signaling), 
and mouse monoclonal anti-FANCM (CP3.2, CV11.1, and CV5.1 anti-γH2AX (05-
636;Millipore), anti-PTEN (6H2.1;Cascade), anti-RAD51 (sc-8349; Santa Cruz), and 
anti-α-tubulin (MS-581-PO; Lab Vision). Band intensity was measured using ImageJ 
software. 
 
In vitro phosphatase assays 
Recombinant FANCM and PTEN were purified as previously described70,71. 20 µL 
reactions containing FANCM (0.2 µg) and/or PLK1 (Invitrogen, 0.2 µg) were incubated 
with 50 µM 32P-ATP in reaction buffer (50 mM Tris, pH7.5, 10 mM MgCl2, 2 mM 
EDTA, 1 mM TCEP) for 30 min. PTEN (0, 0.1, 0.3, 1 µg) was added together with PLK 
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inhibitor BI-2356 (to stop additional phosphorylation from occurring and ensure only 
dephosphorylation was being measured) followed by another 30 min at 30°C. Then 
sample-loading buffer (Invitrogen) was added to stop the reaction. After SDS-PAGE, the 
gel was stained with Instant BLUE (Expedeon), dried and exposed to radiographic film. 
 
Immunofluorescence microscopy 
For immunofluorescence (IF) analyses, cells were seeded in four-well tissue culture 
slides (BD Biosciences) or on cover slips (Corning) and treated with MMC for 18 h. 
Cells were fixed in 4% w/v paraformaldehyde in PBS for 15 min on ice, followed by 
permeabilization for 5 min in 0.3% v/v Triton X-100 in PBS. Fixed cells were incubated 
with primary antibodies in 5% v/v goat serum, 0.1% v/v NP40, in PBS for 1 h, washed 
three times with PBS and then incubated with Alexafluor 488-conjugated anti-mouse or 
anti-rabbit secondary antibodies (Invitrogen) for 45 min. Cells were then counterstained 
and mounted in vectashield plus 406-diamidine-2-phenylindole dihydrochloride (DAPI) 
(Vector Laboratories) and visualized using a Zeiss AxioImager.A1 upright 
epifluorescence microscope with AxioVision LE 4.6 image acquisition software. Primary 
antibodies used for IF were anti-53BP1 (H300; Santa Cruz Biotechnology), anti-DNA-
PKcs pS2056 (ab18192; Abcam), anti-FANCA (ABP6201; Cascade), anti-FANCD2 
(NB100-182; Novus Biologicals and sc-20022; Santa Cruz Biotechnology), anti-FANCI 
(A300-212A; Bethyl Laboratories), anti-FANCM (Meetei and Deans CE56.1 antibodies), 
anti-FK2 (sc-8017; Santa Cruz Biotechnology), and anti-γH2AX (05-636; Millipore). 
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Statistical analysis 
Error bars represent standard errors of the means from three independent experiments. P 
values were calculated using a two-tailed Student’s t-test. 
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Abstract 
Posttranslational modifications (PTMs) are integral for efficient and effective DNA repair 
pathway function.  PTEN is a duel specificity phosphatase where its protein phosphatase 
activity has recently been shown to be necessary for replication dependent DNA repair. 
Not only does PTEN alter the PTM status of replication and repair proteins, but it itself is 
posttranslationally modified, which is essential for its correct localization and activity. 
Here we show that PTEN SUMOylation on K254 is imperative for its DNA repair 
function by signaling its removal from the nucleus in a RNF4 and p97/VCP dependent 
manner. 
 
Introduction 
PTEN is a tumor suppressor protein found to be mutated in many human cancers [1]. It is 
a well-characterized lipid and protein phosphatase involved in several cellular processes 
assaying the integrity of the genome [2]. The major phosphatase function for PTEN is 
dephosphorylation of the lipid second messenger phosphatidylinositol-3,4,5-triphosphate 
(PIP3), opposing the cell proliferating PI3K/AKT pathway [2]. While this tumor 
suppressor function is localized in the cytoplasm, recent publications have shown many 
nuclear tumor suppressor functions that are either protein phosphatase independent or 
dependent [3-7]. Through protein-protein interactions PTEN stabilizes various complexes 
such as the anaphase-promoting complex/cyclosome (APC/C) E3 ubiquitin ligase and its 
subunit CDH1, regulating cell cycle progression [5]. PTEN also creates a complex 
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between RPA and OTUB1 deubiquitinase, resulting in a stabilization of RPA on single-
stranded DNA (ssDNA) [5, 6]. PTEN not only stabilizes RPA at stalled replication forks 
but also recruits and stabilizes RAD51 promoting homologous recombination (HR) [4].   
Two protein substrates for PTEN have recently been identified. First, PTEN targets the 
replisome under replication stress and dephosphorylates MCM2 on S41, stabilizing the 
replication machinery preventing DNA breaks [8]. Secondly, PTEN dephosphorylates 
polo-like kinase 1 (PLK1) on T210 resulting in deactivation of the mitotic kinase and 
destabilization of the protein [7]. Moreover, PTEN phosphorylation by ataxia 
telangiectasia mutated (ATM) on S398 leads to its subsequent SUMOylation on K254 
and its removal from the nucleus upon DNA damage [3]. 
 Recently PTEN has been connected to the Fanconi anemia (FA) DNA repair 
pathway [9]. FA is a DNA repair pathway comprised of 21 genes (FANCA, -B, -C, -
D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, -O/RAD51C, -P/SLX4, -
Q/ERCC4, -R/RAD51, -S/BRCA1, -T/UBE2T, -U/XRCC2 and -V/REV7) that code for 
proteins that specifically removes interstrand crosslinks (ICL) by HR [10-12]. FANCA,   
-B, -C, -E, -F, -G, -L, -T and FA associated proteins FAAP20, and -100 form the FA core 
complex. FANCM recruits the FA core complex to the ICL and the core complex acts as 
an ubiquitin E3 ligase that monoubiquitinates FANCD2 and FANCI on K561 and K523 
respectively [10, 13]. Monoubiquitinated FANCD2 and I accumulates at sights of DNA 
damage and recruits nucleases to excises the ICL and promote HR by the downstream FA 
proteins, FANCD1, -J, -N, -O, -R, -S, -U, and -V.  
 DNA repair needs to be carefully orchestrated for proper protein recruitment and 
function at sites of DNA damage. Many DNA repair proteins are posttranslationally 
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modified throughout the DNA repair process. It is well known that protein 
phosphorylation acetlylation, methylation, and ubiquitination are involved in protein 
signaling and activation throughout the DNA repair process.  Recently, it has been shown 
that proteins are polySUMOylated, forming SUMO2/3 chains signaling, for subsequent 
polyubiquitination and proteasomal degradation [14-16]. 
 SUMOylation of proteins can stimulate protein-protein interactions through the 
contact of a SUMO-interacting motif (SIM) on the recruited protein.  The SUMO-
targeted E3 ubiquitin ligase (STubL), RNF4, contains multiple SIMs to interact with 
SUMO2/3 chains [17].  Through RNF4’s RING domain and the assistance of an E2 
ubiquitin-conjugating enzyme, RNF4 polyubiquitinates SUMOylated proteins for 
removal and subsequent degradation. Many DNA repair proteins are regulated by RNF4 
mediated degradation to allow downstream DNA damage response (DDR) proteins 
access to the damage [14]. The protein complexes are removed from chromatin by 
chromatin-associated degradation [18]. Chromatin-associated degradation is a process in 
which the protein targets are SUMOylated followed by subsequent poly-ubiquitination 
targets the AAA+ ATPase p97/VCP [19]. Using ATP hydrolysis, p97/VCP extracts 
proteins from chromatin targeting the substrates to the 26S proteasome [20]. 
 In this study, we have investigated the role of PTEN SUMOylation in response to 
DNA damage. We have established an increase in PTEN-SUMO upon DNA damage 
with various DNA damaging agents as well as a robust increase in PTEN-SUMO with 
inhibition of the proteasome. By observing the nuclear pool of PTEN, we see a 
stabilization of PTEN when either RNF4 is knocked down using siRNA or p97/VCP is 
chemically inhibited. When the SUMOylation incompetent missense mutant PTEN-
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K254R is stably expressed in PTEN null cells, we observe an impairment of DNA repair 
by an increase in chromosome aberrations. Further investigation narrowed PTEN’s 
genome instability to failure to activate the Fanconi anemia (FA) DNA repair pathway. 
We observe a defect in the accumulation of FANCA, -M, -D2, and –I at sites of DNA 
damage via immunofluorescence microscopy. Lastly, it was previously shown that PTEN 
SUMOylation signals its removal from the nucleus [3]. We observe stabilization in 
nuclear PTEN-K254R compared to wild type upon DNA damage. Our results uncover a 
novel mechanism of the regulation of PTEN during DNA repair, specifically by HR. 
 
Results 
PTEN SUMOylation targets PTEN for degradation 
SUMOylation has recently been connected to DNA repair regulating protein turnover and 
the kinetics of proteins throughout the repair process [14]. We previously uncovered a 
connection between PTEN and the Fanconi anemia DNA repair pathway independent of 
its lipid phosphatase activity [9]. Furthermore, PTEN is SUMOylated on K254 and PTEN 
null cells expressing the SUMO incompetent mutant K254R have increased genome 
instability upon irradiation treatment [3]. To determine if PTEN SUMOylation is 
important for interstrand crosslink (ICL) repair we grew COS-7 cells in the absence or 
presence of mitomycin C (MMC) and observed PTEN SUMOylation. When treated with 
MMC, we see a strong induction of the higher molecular weight band, which Bassi et al 
has shown to be the SUMOylated form of PTEN (Figure 1A) [3].  By inhibiting the 
proteasome with MG132, we can see a strong increase in stability of PTEN-SUMO in 
COS-7, BJ-TERT and U2OS cell lines (Figure 1B) suggesting that PTEN-SUMO is  
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Figure 1. PTEN SUMOylation targets PTEN for degradation 
(A) COS-7 cells were treated with or without 100 nM MMC for 24h. Whole cell lysates 
were prepared and immunoblotted for PTEN, and α-tubulin. To improve clarity and 
conciseness, the presented blots have been cropped. All gels were run under the same 
experimental conditions. 
(B) COS-7, U2OS, and BJ-TERT cells were treated with 10 µM of MG132 for 16h. 
Whole cell lysates were prepared and immunoblotted for PTEN and FANCD2 as labeled 
on the left. To improve clarity and conciseness, the presented blots have been cropped. 
All gels were run under the same experimental conditions. 
(C and D) COS-7 cells were treated with either 1mM hydroxyurea (HU) (C) or 0.4 µM 
VP16 (D) and with or without 2.5 µM MG132 for 16h. Whole cell lysates were prepared 
and immunoblotted for PTEN, FANCD2 and α-tubulin.  
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targeted for degradation. To determine if PTEN-SUMO is involved in not only ICL 
repair, but also double strand break (DSB) repair (Figure 1C and D), we treated COS-7 
with a DNA damaging agent, hydroxyurea (HU), a proteasome inhibitor MG132, or 
cotreatment to prevent PTEN degradation. We see an increase in PTEN-SUMO when 
treated with HU and MG132 compared to MG132 alone (Figure 1C). This was also seen 
with COS-7 cells treated with the topoisomerase inhibitor VP16, causing double strand 
breaks, and MG132 (Figure 1D). The large induction of PTEN-SUMO with cotreatment 
of MG132 and DNA damaging agents suggests that PTEN-SUMO signals PTEN for its 
degradation.  
 
SUMOylated PTEN is targeted for RNF4 and p97/VCP mediated degradation 
RNF4 is a SUMO targeted E3 ubiquitin ligase that has been previously linked to DNA 
repair, helping to orchestrate the spatial coordination of the many proteins involved [14]. 
For example, RNF4 is targeted to polySUMO RPA through its SUMO interacting motifs 
(SIMs) for polyubiquitination and proteasomal degradation to allow for the efficient 
loading of RAD51 on the now free ssDNA for HR [14].  Since PTEN-SUMO increases in 
stability when the proteasome is inhibited, we wanted to see if SUMOylation of PTEN on 
K254 targets PTEN for proteasome degradation. To test this we knocked down RNF4 
using targeted small interfering RNA (siRNA) and treated with HU, MG132, or 
cotreatment. Since PTEN is SUMOylated in order to remove it from the nucleus, we 
performed a cellular fractionation for a nuclear enrichment [9]. When looking at the 
nuclear pool of PTEN, depletion of RNF4 stabilized PTEN. There is also an increase in 
PTEN-SUMO upon depletion of RNF4 (Figure 2A). More importantly, we see a 
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Figure 2. Nuclear PTEN is targeted for degradation by RNF4 and p97/VCP  
(A) HeLa cells were transfected with non-targeting siRNA (siCtrl.) or on target siRNA 
(siRNF4) for 96h and treated with 1 mM HU or 2.5 µM MG132 for the last 16h. 
Cytoplasmic proteins were removed and nuclear enriched lysates were prepared and 
immunoblotted for PTEN, RNF4, and H2A. 
(B) HeLa cells were treated with 2.5 µM NMS-873 for 8 and 24h or 5 µM NMS-873 for 
8 h. Cytoplasmic proteins were removed and nuclear enriched lysates were prepared and 
immunoblotted for PTEN, and H2A.  
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large increase in PTEN stability with untreated siRNF4 compared to siCtrl. (lane 5 vs 1).  
PolySUMO and ubiquitin chains allow for binding of the Type II AAA+ ATPase, 
p97/VCP, and recruitment to the 26S proteasome [20]. By using the p97/VCP small 
molecule inhibitor NMS-873, we also see stabilization of nuclear PTEN (Figure 2B). 
These results suggest that the nuclear pool of PTEN is regulated by proteasomal 
degradation mediated by RNF4 and p97/VCP. 
 
PTEN SUMOylation is important for DNA Repair 
To gain further mechanistic insight into the role of PTEN in ICL repair, we 
complemented HCT116 PTEN-/- cells with LacZ, wild type PTEN, and SUMOylation-
incompetent PTEN-K254R [3, 21, 22]. The PTEN variants behaved as predicted with 
wild type and PTEN-K254R able to down-regulate the PI3K/AKT pathway, as 
demonstrated by loss of AKT-pS473 signal, while the phosphatase defective C124S and 
lipid phosphatase defective G129E mutants are unable to deactivate AKT (Figure 3A). 
We exposed the HCT116 PTEN-/- + LacZ, -PTEN-WT, and -PTEN-K254R cells to MMC 
and analyzed metaphase chromosomes for the presence of gaps, breaks, and radial 
formations. Only wild type PTEN rescued the sensitivity of PTEN-/- cells to MMC-
induced chromosome damage, while PTEN-K254R failed to rescue the ICL sensitivity of 
PTEN-/- cells (Figure 3B and C). Cells stably expressing PTEN-K254R exhibited 
increased chromosome gaps and breaks and radial formations, compared with cells 
expressing wild-type PTEN, following exposure to MMC (P < 0.001) (Figure 3B).  
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Figure 3. PTEN function in ICL repair is SUMOylation-dependent 
 (A) HCT116 PTEN-/- cells were stably transduced with pLenti6.2-LacZ, -PTEN-WT, -
PTEN-C124S, -PTEN-G129E, and -PTEN-K254R. Whole-cell lysates were prepared and 
immunoblotted for PTEN, AKT, AKT pS473, RAD51, and α-tubulin.  
(B) PTEN-K254R fail to rescue the sensitivity of PTEN-/- cells to the clastogenic effects 
of mitomycin C (MMC), in contrast to PTEN-WT. Cells were incubated in the absence 
(NT) or presence of 20 nM MMC for 24 h and metaphase spreads were analyzed for 
structural chromosome aberrations. ***P < 0.001. 
(C) Images of PTEN-K254R chromosome aberrations observed in B compared to PTEN-
WT. 
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Functional FANCD2 and FANCI is dependent on PTEN SUMOylation 
To determine the status of the FA pathway in PTEN-/- + LacZ, -PTEN-WT, and PTEN-
K254R cells, we examined the activation of FANCD2 and its binding partner FANCI. 
FANCD2 and FANCI form a heterodimer called the ID2 complex. The 
monoubiquitination of FANCD2 and FANCI by the FA core complex is a key activation 
step of the pathway [23]. Activated FANCD2 and FANCI converge at sites of DNA 
damage, which can be visualized as nuclear foci via immunofluorescence [23]. Analysis 
of FANCD2 and FANCI nuclear foci formation in the HCT116 PTEN-/- + LacZ, -PTEN-
WT, and -PTEN-K254R cells revealed inefficient MMC-inducible FANCD2 and FANCI 
nuclear foci formation in PTEN-/- cells stably expressing PTEN-K254R, similar to cells 
expressing LacZ (Figures 4A and B). Since PTEN-K254R is deficient in FANCD2 and 
FANCI nuclear localization, we next examined the nuclear localization of the FA core 
complex. We have previously determined that PTEN-/- cells and PTEN-/- cells expressing 
the protein phosphatase defective missense mutant C124S, are defective in the FA DNA 
repair pathway via deficient core complex recruitment and FANCD2 and FANCI 
activation [9]. From this we were interested in determining if PTEN SUMOylation is 
important for efficient FA core recruitment to sites of DNA damage. HCT116 PTEN-/- + 
LacZ, -PTEN-WT, and -PTEN-K254R were incubated in the absence or presence of 
MMC and FANCA and FANCM nuclear foci formation were analyzed. While wild type 
PTEN rescued defective ICL-inducible FANCA and FANCM nuclear foci formation, the 
PTEN-K254R mutant did not (Figures 4C and D). This suggests that PTEN 
SUMOylation on K254 is important for ICL repair via activation of the FA DNA repair 
pathway.  
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Figure 4. FA pathway activation is dependent on PTEN SUMOylation 
(A and B) Defective FANCD2 (A) and FANCI (B) nuclear foci formation in PTEN-/- 
cells expressing LacZ, and PTEN-K254R. Cells were incubated in the absence (NT) or 
presence of 200 nM MMC for 18 h and let recover for 0, 4, and 8 h. ***P < 0.001. 
(C and D) Defective FANCA (A) and FANCM (B) nuclear foci formation in PTEN-/- 
cells expressing LacZ, and PTEN-K254R. Cells were incubated in the absence (NT) or 
presence of 200 nM MMC for 18 h. ***P < 0.001.  
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SUMOylated PTEN signals for its Nuclear Exclusion 
Posttranslational modifications such as monoubiquitination and SUMOylation can target 
a protein for cellular compartmentalization. An example of this is the monoubiquitination 
of PTEN, which has been shown to signal its nuclear localization [24]. Recent studies 
have suggested that PTEN SUMOylation promotes its nuclear export [3]. To determine if 
PTEN SUMOylation affects its cellular localization we treated HCT116 and MCF10A 
PTEN-/- +PTEN wild type and +PTEN-K254R with MMC and performed a cellular 
fractionation. Consistent with the findings of Bassi et al, we observed increased PTEN-
K254R stability and less efficient removal of PTEN-K254R from chromatin following 
ICL exposure, compared with wild type PTEN (Figure 5). 
 
PTEN SUMOylation is dependent on FANCD2 
Since PTEN-/- cells have impairment in HR via the Fanconi anemia pathway, we assessed 
PTEN-SUMO in FA-D2 patient cells lacking functional FANCD2 protein. Increased 
PTEN-SUMO induction upon MG132 treatment was observed in FA-D2+FANCD2 cells 
compared to FA-D2 cells (Figure 6A). With further investigation, the analysis of 
FANCD2 ChIP-seq data showed that FANCD2 binds to DNA in the middle of the E3 
SUMO ligase gene PIAS1 [25]. Since we observe deficient PTEN SUMOylation in FA-
D2 cells we then analyzed the protein expression of PIAS1. We observed a stark decrease 
in protein levels of PIAS1 in FA-D2 cells compared to FA-D2+FANCD2 and FA-
FANCD2-K561R (monoubiquitination deficient mutant) (Figure 6B).  These results 
indicate a complex relationship between FANCD2 and PTEN PTM. Interestingly, it also 
implies an FA DNA repair independent role for FANCD2 in the transcriptional regulation  
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Figure 5. SUMOylated PTEN signals for its Nuclear Exclusion 
(A and B) HCT116-PTEN-/- + PTEN or + PTEN-K254R (A) and MCF10A-PTEN-/-
+PTEN or +PTEN-K254R (B) were treated in the absence or presence of 200 nM MMC 
for 18h and a cellular fractionation was performed. W represents whole cell lysate, S is 
soluble cytoplamic and nuclear proteins and C is chromatin bound proetins. Lysates were 
prepared and immunoblotted for PTEN, H2A and α-tubulin. The ratio of C:W was 
measured using ImageJ software. 
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of the PIAS1 gene.  
Discussion  
PTEN is a ubiquitous protein throughout the cell that is involved in many cellular 
activities [26]. Because of this, PTEN is heavily posttranslationally modified [26]. These 
modifications regulate PTEN’s activity and cellular localization. For example, PTEN 
monoubiquitination on two lysine residues 13 and 289 leads to PTEN’s nuclear 
localization [24]. It has also been shown that PTEN is SUMOylated on residue K254 and 
this SUMOylation exports PTEN from the nucleus and SUMOylation of PTEN is integral 
to its role in DNA repair shown by prolonged γH2AX nuclear foci after irradiation and 
decrease HR by a HR assay in PTEN-K254R cells compared to PTEN-WT U87MG cells 
[3]. It is still unclear the mechanism behind PTEN-SUMO and how it was involved in 
DNA repair.  Here we show that PTEN SUMOylation increases after DNA damage and 
targets it for proteolytic degradation mediated by the SUMO targeted ubiquitin ligase, 
RNF4 and the AAA+ ATPase, p97/VCP. 
 By inhibiting the proteasome with MG132 we see a large induction of PTEN-
SUMO compared to NT. But when treated with various DNA damaging agents (MMC, 
HU, and VP16) and MG132, we see a larger increase in PTEN-SUMO compared to 
solely MG132 treatment indicating PTEN is SUMOylated upon DNA damage and 
degraded since it is easily visualized by inhibiting the proteasome. We have established a 
requirement for PTEN SUMOylation on residue K254 in ICL repair. PTEN-K254R fails 
to restore efficient FANCD2 and FANCI nuclear foci formation through impaired 
recruitment of the FA core complex causing deficient ICL repair in PTEN-/- cells. 
Accordingly, we observed increased PTEN-K254R stability and less efficient removal of 
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PTEN-K254R from chromatin following ICL exposure. This is due to the removal by 
p97/VCP targeting the polySUMO and ubiquitinated PTEN. Using small interfering 
RNA we can knock down protein expression of the ubiquitin E3 ligase RNF4, we see a 
stabilization of not only non SUMO PTEN but also SUMOylated PTEN. By chemically 
inhibiting p97/VCP, PTEN-SUMO is also stabilized. 
 The regulation of DDR proteins by SUMOylation has recently been connected to 
DSB repair for both HR and nonhomologous end joining (NHEJ) pathways [14]. During 
HR, the RPA complex binds to ssDNA protecting the DNA from nucleolytic degradation. 
To allow RAD51 to then bind to the ssDNA to form the nucleofilament for strand 
invasion, RPA1 of the complex is SUMOylated targeting it to be polyubiquitinated by 
RNF4. This results in its subsequent degradation and freeing up the ssDNA for RAD51 
loading [14]. MDC1 is also removed from DNA by SUMOylation followed by 
ubiquitination by RNF4 to allow for the next steps in NHEJ. More recently, the 
regulation by SUMO was connected to the FA pathway [15]. Monoubiquitinated 
FANCD2 and FANCI (ID2) are recruited to DNA crosslinks. To regulate the dosage of 
activated ID2 at sites of DNA damage, SUMOylation by an E3 SUMO ligase PIAS1 or 
PIAS4 and polyubiquitination by RNF4 targets ID2 for removal via p97/VCP [15].  
 Taken together that PTEN SUMOylation is important for ICL repair, we 
hypothesize that PTEN dephosphorylates one or more key substrates. Following 
dephosphorylation, PTEN SUMOylation and its targeted degradation may be necessary 
to facilitate subsequent DNA repair steps or enable replication fork resumption following 
removal of the ICL block (Figure S2).  These results establish that PTEN functions in the 
activation of the FA pathway, and that DNA repair is dependent on its protein 
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phosphatase activity and ability to undergo SUMOylation on K254. Lastly, uncovering 
decreased PTEN-SUMO in FA-D2 may be caused by decreased transcription of PIAS1 
require extensive research to determine the relationship. 
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Figure 6. PTEN SUMOylation is dependent on FANCD2 
(A) PD20F (FA-D2) and PD20F+FANCD2 (FA-D2+FANCD2) were grown in the 
absence or presence of 5 µM of MG132 for 8 or 16h. Whole-cell lysates were prepared 
and immunoblotted for PTEN, FANCD2, and α-tubulin. LE is light exposure and DE is a 
darker exposure of the same blot.  
(B) PD20L-pMMP-empty, -FANCD2, and -FANCD2-K561R were grown in the absence 
or presence of 200 nM MMC for 18h. Whole-cell lysates were prepared and 
immunoblotted for PTEN, FANCD2, and α-tubulin.  
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Materials and Methods 
Cell culture  
HCT116 PTEN+/+, PTEN-/- #22, and PTEN-/- #35[27] (a kind gift from Todd Waldman, 
Lombardi Cancer Center, Georgetown University) were grown in McCoy’s medium 
supplemented with 12% v/v FBS, 1% v/v L-glutamine, and 1% v/v 
penicillin/streptomycin. MCF10A PTEN+/+ and PTEN-/- cells (Horizon Discovery, U.K.) 
were grown in DMEM F12 supplemented with 5% v/v horse serum, 20 ng/ml epidermal 
growth factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 µg/ml insulin, 1% 
v/v L-glutamine, and 1% v/v penicillin/streptomycin. Stably complemented HCT116 and 
MCF10A lines were generated by transduction with pLenti6.2/V5-DEST (Invitrogen) 
lentivirus harboring wild type or mutant PTEN cDNAs. HCT116 and MCF10A stable 
cell lines were grown in McCoy’s or DMEM F12 medium respectively supplemented 
with 5 µg/ml blasticidin.  FA-D2 (FANCD2hy/-) cells were purchased from Coriell Cell 
Repositories (Catalog ID GM16633)[28]. Corrected FA-D2 cells were generated by 
transduction with pLenti6.2-FANCD2 lentivirus, followed by selection in DMEM 
supplemented with 15% v/v FBS, 1% v/v L-glutamine, 1% v/v penicillin/streptomycin 
and 2 µg/ml blasticidin. PD20L cells were grown in RPMI media supplemented with 
20% v/v FBS, 1% v/v L-glutamine, and 1% v/v penicillin/streptomycin and 1 µg/ml 
puromycin. HeLa, BJ-TERT, COS-7, and U2OS cells were grown in DMEM 
supplemented with 12% v/v FBS, 1% v/v L-glutamine, and 1% v/v 
penicillin/streptomycin.  
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Plasmids and site-directed mutagenesis 
The plasmids pSG5L-HA-PTEN wild type (Addgene) was used to amplify PTEN cDNA 
using the forward primer 5’-CACCATGACAGCCATCATCAAA-3’ and the reverse 
primer 5’-TCAGACTTTTGTAATTTGTGTATGCTG-3’. The cDNA was then 
recombined into pLenti6.2/V5-DEST (Invitrogen) using Invitrogen Gateway Cloning.  
The PTEN-K254R cDNA was generated by site-directed mutagenesis of the wild type 
PTEN cDNA using the Quikchange Site-directed Mutagenesis Kit (Stratagene). The 
forward and reverse oligonucleotide sequences used are as follows: 
FP  5’-CGTTACCTGTGTGTGGTGATATCCGAGTAGAGTTCTTCCACAAAC-3’ 
RP 5’-GTTTGTGGAAGAACTCTACTCGGATATCACCACACACAGGTAACG-3’. 
 
Cellular fractionation  
Soluble proteins were removed by extraction in cytoskeletal buffer (CSK) (10 mM PIPES 
pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA, and 0.5% v/v 
Triton-X-100) for 10 minutes at 4oC. For nuclear enrichment, pellets were washed once 
with CSK buffer, lysed in SDS sample buffer (2% w/v SDS, 50 mM Tris-HCl pH 7.4, 10 
mM EDTA), boiled for 15 min, followed by sonication for 10 s at 10% amplitude using a 
Fisher Scientific Model 500 Ultrasonic Dismembrator. For the second cellular 
fractionation assay, cell pellets were resuspended in Cytoplasmic buffer (10mM HEPES 
pH7.9, 10 mM KCl, 1.5m m MgCl2, 340mM Sucrose, 10% glycerol, 1 mM DTT,  0.1 % 
v/v Triton-X-100, and Rouch Protease Inhibitor cocktail)  and centrifuged at 1,000 x g  
for 5 min for soluble cytoplasmic proteins extraction. Pellets were then resuspended in 
chilled nuclear lysis buffer (10 mM HEPES pH7.9, 3 mM EDTA, 0.2 mM EGTA, and 
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Rouch Protease Inhibitor cocktail) on ice for 15 minutes with occasional vortexing to 
remove nuclear soluble proteins. The remaining pellet containing chromatin bound 
proteins were lysed in SDS sample buffer (2% w/v SDS, 50 mM Tris-HCl pH 7.4, 10 
mM EDTA), boiled for 15 min, followed by sonication for 10 s at 10% amplitude using a 
Fisher Scientific Model 500 Ultrasonic Dismembrator. 
  
Chromosome breakage assay 
For chromosome breakage assays, cells were incubated in the absence or presence of 
MMC for 18-24 h. Prior to harvesting, cells were treated with 0.1 µg/ml Colcemid 
(Gibco/Invitrogen) for 2 h. Cell pellets were incubated in 0.075 M KCl at 37°C for 18 
min, followed by fixation in Carnoy’s fixative (3:1 methanol:glacial acetic acid) with 
multiple changes. Cells were dropped onto chilled slides and air-dried prior to staining 
with 2.5% w/v Giemsa solution (Sigma). Metaphases were analyzed using a Zeiss 
AxioImager.A1 upright epifluorescent microscope with AxioVision LE 4.6 image 
acquisition software. 
 
Immunoblotting and antibodies 
For immunoblotting analysis, cell suspensions were washed in ice-cold PBS and lysed in 
50 mM Tris.Cl pH 7.4, 1.0% v/v NP-40, 0.25% w/v Deoxycholic acid, 150 mM NaCl, 1 
mM EGTA, 1 mM PMSF, 1 mM Na3O4V, 1 mM NaF, plus protease inhibitors cocktail 
(Roche). Proteins were resolved on NuPAGE 3-8% w/v Tris-Acetate or 4–12% w/v Bis-
Tris gels (Invitrogen) and transferred to polyvinylidene difluoride (PVDF) membranes. 
The following antibodies were used: Rabbit anti-AKT (Cell Signaling), anti AKT-pS473 
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(Cell Signaling), anti-FANCA (ABP6201; Cascade), anti-FANCD2 (NB100-182; Novus 
Biologicals), anti-H2A (07-146; Millipore), anti-PIAS1 (Cell Signaling) and anti-PTEN 
(9559;Cell Signaling). Mouse monoclonal: anti-RAD51 (sc-8349; Santa Cruz), and anti-
α-tubulin (MS-581-PO; Lab Vision).  
 
Immunofluorescence microscopy 
For immunofluorescence (IF) analyses, cells were seeded in four-well tissue culture 
slides (BD Biosciences) or on cover slips (Corning) and treated with MMC for 18 h. 
Cells were fixed in 4% w/v paraformaldehyde in PBS for 15 min on ice, followed by 
permeabilization for 5 min in 0.3% v/v Triton X-100 in PBS. Fixed cells were incubated 
with primary antibodies in 5% v/v goat serum, 0.1% v/v NP40, in PBS for 1 h, washed 
three times with PBS and then incubated with Alexafluor 488-conjugated anti-mouse or 
anti-rabbit secondary antibodies (Invitrogen) for 45 min. Cells were then counterstained 
and mounted in vectashield plus 406-diamidine-2-phenylindole dihydrochloride (DAPI) 
(Vector Laboratories) and visualized using a Zeiss AxioImager.A1 upright 
epifluorescence microscope with AxioVision LE 4.6 image acquisition software. Primary 
antibodies used for IF were anti-FANCA (ABP6201; Cascade), anti-FANCD2 (NB100-
182; Novus Biologicals and sc-20022; Santa Cruz Biotechnology), anti-FANCI (A300-
212A; Bethyl Laboratories), anti-FANCM (Meetei and Deans CE56.1 antibodies). 
 
siRNA experiments 
Cells were plated in six-well dishes at a density of 200,000 cells/well and transfected the 
following day with RNF4-specific (siRNF4), or control, non-targeting siRNA (siCtrl) 
 97 
using Lipofectamine 2000 (Invitrogen). Seventy-two hours following transfection, cells 
were incubated in the absence or presence of MMC and harvested for nuclear enrichment 
as described above. The following sense and anti-sense sequences were used: siRNF4 
(MWG Operon) 5’-GAAUGGACGUCUCAUCGUU-3’ 5’-
AACCAUGAGACGUCCAUUC-3’ and for non-targeting siCtrl (Dharmacon) 5’-
UAACGACGCGACGACGUAA-3’ and 5’-UUACGUCGUCGCGUCGUUA-3’. 
 
Statistical analysis 
Error bars represent standard errors of the means from three independent experiments. P 
values were calculated using a two-tailed Student’s t-test. 
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APPENDIX I 
Conclusion 
 The mechanistic insight of the role of PTEN in genome stability is essential for 
efficient DNA repair and cell cycle progression. Recently, great efforts have uncovered 
several unique cellular processes in how PTEN functions as a tumor suppressor 
independent of its cytoplasmic lipid phosphatase activity. PTEN was first shown to have 
a separate nuclear function by interacting with the kinetochore, stabilizing chromosomes 
at the centromere, and regulating transcription of the essential homologous recombination 
protein, RAD51, mRNA with the transcription factor E2F1 [1]. The result of the 
transcriptional regulation of RAD51 has remained controversial and has led to an intense 
investigation to understand the mechanism behind nuclear PTEN [2, 3].  It has now been 
discovered that PTEN stabilizes replication forks when the replication machinery 
encounters DNA lesions [4, 5]. PTEN protects the ssDNA by stabilizing RPA through the 
recruitment of its deubiquintating enzyme, OTUB1 [5].  Following the stabilization of 
ssDNA, PTEN then localizes RAD51 to the stalled replication fork, promoting error free 
DNA repair via homologous recombination [4].  
 Not only is PTEN involved in ensuring efficient DNA replication during S phase, 
PTEN posttranslational modification by phosphorylation on residue S380 by PLK1 
allows for timely cell cycle entrance and exit of M phase [6, 7]. Improper regulation of 
PTEN through M phase leads to deregulation of chromosome segregation and increase 
aneuploidy in PTEN-deficient cells. Aneuploidy is a genetic phenotype and 
characterization of cancer cells.  Several layers regulate the control of the proportion of 
PTEN phosphorylated on S380. PTEN dephosphorylates PLK1 on T210 and this 
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phosphorylation of T210 is necessary for PLK1 kinase activity [8]. PTEN then stabilizes 
the APC/C-CDH1 E3 ubiquitin ligase complex targeting many mitotic proteins for 
proteasomal degradation, such as PLK1 [9]. It was also shown that PTEN-pS380 is an 
APC/C-CDH1 target for its removal from chromatin for G1 entrance, indicating a 
complex and dynamic relationship between PTEN and PLK1 with ubiquitin mediated 
proteolytic degradation by the APC/C-CDH1 complex [7]. 
 The main focus of my dissertation was identifying a phosphatase involved in the 
Fanconi anemia DNA repair pathway which specifically removes interstrand cross links 
(ICls). PTEN became the best candidate since it recently was connected to DNA repair 
and is one of the ten familial breast and ovarian cancer susceptibility genes. The majority 
of these susceptibility genes are Fanconi anemia genes themselves or biochemically 
linked to the pathway [10]. The one outlier of the group was PTEN, which happens to be 
a bona fide phosphatase tumor suppressor.  Using isogenic PTEN+/+ and PTEN-/- non-
transformed mammary epithelial cells (MCF10A) and transformed colorectal carcinoma 
cell line (HCT116), we determined PTEN-/- cells have an FA patient cell like phenotype 
with increased sensitivity to DNA cross linking agents such as MMC with decreased cell 
survival and increased chromosome aberrations. We discovered that this was due to 
improper recruitment of the FA core complex and FANCD2 and FANCI to DNA 
damage, resulting in PTEN-/- cells favoring error prone nonhomologous end joining over 
error free homologous recombination. This was caused by increased PLK1 activity since 
PTEN normally deactivates PLK1 by dephosphorylation and enhances its protein 
degradation by stabilizing the APC/C-CDH1 complex. Without PTEN, there is increased 
PLK1 activity, and it is known that PLK1 phosphorylates FANCM, priming FANCM for 
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its degradation leading to deficient FA core complex recruitment and a nonfunctional FA 
pathway [11].  We also determined that PTEN’s role in ICL repair is dependent on its 
protein phosphatase activity by comparing the phosphatase deficient missense mutant 
C124S to the lipid phosphatase deficient G129E. This is interesting since PTEN targets 
PLK1. It is still unknown if PTEN dephosphorylates any FA proteins. 
 PTEN SUMOylation on residue K254 was shown to be important for protection 
from IR damage [2]. We also see a dependence of SUMOylation of K254 by 
characterizing the SUMO incompetent missense mutant K254R in ICL repair via the FA 
pathway see the same phenotype as PTEN-/-cells. We next tried to understand the 
mechanism behind how PTEN SUMOylation on residue K254 protects cells from DNA 
damage. We determined PTEN SUMOylation targets its degradation and removal from 
the nucleus by RNF4 polyubiquitination, resulting in PTEN transportation to the 26S 
proteasome by p97/VCP. In preliminary data, we also discovered PTEN SUMOylation is 
dependant on FANCD2 by FANCD2 transcription regulation of the E3 SUMO ligase 
PIAS1. It is still not fully understood why PTEN is removed from the nucleus upon DNA 
damage while resulting in genome stability. Our working hypothesis is that PTEN 
dephosphorylates one or more proteins involved in DNA repair resulting in their 
deactivation. This would mean that PTEN removal would allow its protein phosphatase 
substrates to stay active only to be deactivated once PTEN has localized back in the 
nucleus. 
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Supplemental information for manuscript II: “The PTEN phosphatase functions 
cooperatively with the Fanconi anemia proteins in DNA crosslink repair” 
 
 
Supplementary information: 
 
Materials and Methods 
Antibody generation 
FANCM monoclonal antibodies were generated by intra-peritoneal injection of 
recombinant purified FANCM peptide (His-tagged amino acids 1507-1647 purified from 
E. coli using Nickel-NTA resin under guanidine-HCl denaturing conditions). Standard 
hybridoma generation protocols were employed using Sp2/0-Ag14 murine myeloma 
cells, followed by single cell cloning of the highest titer lines. Independently derived 
monoclonal antibodies CE56.1, CP3.2, CV5.1, and CV11.1 were purified from 
hybridoma supernatants using protein A sepharose, and shown to detect a single band of 
230 kDa by Western blotting, that is absent in FANCM siRNA treated cells (see Figure 
S9). 
 
Plasmids and site-directed mutagenesis 
The plasmids pSG5L-HA-PTEN wild type, -PTEN-C124S, -PTEN-G129E and pHR-
SIN-PTEN-Y138L (Addgene) were used to amplify PTEN cDNA using the forward 
primer 5’-CACCATGACAGCCATCATCAAA-3’ and the reverse primer 5’-
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TCAGACTTTTGTAATTTGTGTATGCTG-3’. The cDNAs were then recombined into 
pLenti6.2/V5-DEST (Invitrogen) using Invitrogen Gateway Cloning.  
 
Cellular fractionation 
Soluble proteins were removed by extraction in cytoskeletal buffer (CSK) (10 mM PIPES 
pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA, and 0.5% v/v 
Triton-X-100) for 10 minutes at 4oC. Pellets were washed once with CSK buffer, lysed in 
SDS sample buffer (2% w/v SDS, 50 mM Tris-HCl pH 7.4, 10 mM EDTA), boiled for 15 
min, followed by sonication for 10 s at 10% amplitude using a Fisher Scientific Model 
500 Ultrasonic Dismembrator. 
 
Chromosome breakage and cytotoxicity assays 
For chromosome breakage assays, cells were incubated in the absence or presence of 
MMC for 18-24 h. Prior to harvesting, cells were treated with 0.1 µg/ml Colcemid 
(Gibco/Invitrogen) for 2 h. Cell pellets were incubated in 0.075 M KCl at 37°C for 18 
min, followed by fixation in Carnoy’s fixative (3:1 methanol:glacial acetic acid) with 
multiple changes. Cells were dropped onto chilled slides and air-dried prior to staining 
with 2.5% w/v Giemsa solution (Sigma). Metaphases were analyzed using a Zeiss 
AxioImager.A1 upright epifluorescent microscope with AxioVision LE 4.6 image 
acquisition software. For the cell proliferation assay, cells were plated at 10,000 
cells/well, treated in the absence or presence of various concentrations of MMC for 48 h 
and the CellTiter 96® AQueous One Solution Reagent (Promega) was added directly to 
cultured cells, incubated for 2 h and the absorbance at 490 nm was measured with a 96-
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well Bio-Rad 680 microplate reader. For the MMC survival assay, cells were plated at a 
density of 10,000 cells/well in 6-well dishes and treated with MMC the following day for 
7 days. Cells were then fixed with 10% v/v methanol and 10% v/v acetic acid, stained 
with 1% w/v crystal violet in methanol, extracted with 0.02% SDS in methanol, and the 
absorbance at 595 nm was measured with a 96-well Bio-Rad 680 microplate reader. 
 
siRNA experiments 
Cells were plated in six-well dishes at a density of 200,000 cells/well and transfected the 
following day with PTEN-specific (siPTEN), FANCD2-specific (siFANCD2), or control, 
non-targeting siRNA (siCtrl) using Lipofectamine 2000 (Invitrogen). Seventy-two hours 
following transfection, cells were incubated in the absence or presence of MMC and 
harvested for cytogenetic analysis as described above. The following sense and anti-sense 
sequences were used: siFANCD2 (Dharmacon) 5’-CAGCCUACCUGAGAUCCUA-3’ 
and 5’-UAGGAUCUCAGGUAGGCUG-3’ and for non-targeting siCtrl (Dharmacon) 5’-
UAACGACGCGACGACGUAA-3’ and 5’-UUACGUCGUCGCGUCGUUA-3’. PTEN 
siRNAs (siGENOME SMARTpool siRNA reagent D-001810-01-05) were obtained from 
Thermo Fisher Scientific. 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
 
 
Figure S1. PTEN-/- cells are hypersensitive to mitomycin C 
(A) HCT116 PTEN+/+ and two independent clones of PTEN-/- cells were incubated in the 
absence or presence of the indicated concentrations of MMC for 7-10 days, and cell 
survival was determined using a crystal violet assay. (B) MCF10A PTEN+/+ and PTEN-/- 
cells were incubated in the absence or presence of the indicated concentrations of MMC 
for 7-10 days and cell survival determined. (C and D) MCF10A PTEN+/+ and PTEN-/- 
cells were incubated in the absence or presence of the indicated concentrations of MMC 
for 24 h and metaphase spreads were analyzed for chromosome aberrations. (C) Numbers 
of centromere aberrations observed in PTEN+/+ and PTEN-/- cells and (D) representative 
images of centromere aberrations observed in PTEN-/- cells. ***, P < 0.001. 
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Figure S2. PTEN is required for efficient mitomycin C-inducible FANCD2 and 
FANCI nuclear foci formation, but not for the localization of FANCD2 and FANCI 
to chromatin 
(A) Chromatin fractionation analysis of lysates from HCT116 PTEN+/+ and PTEN-/- cells 
reveals efficient localization of FANCD2, FANCI, and RAD51 to chromatin following 
mitomycin C (MMC) treatment. Cells were incubated in the absence (NT) or presence of 
200 nM MMC for 24 h. W, unfractionated whole-cell lysate; S, soluble cytoplasmic and 
nuclear fraction; C, chromatin-enriched fraction. (B and C) MCF10A PTEN+/+ and PTEN-
/- cells were incubated in the absence or presence of 200 nM MMC for 18 h, allowed to 
recover for 8 h, and FANCD2 (B) and FANCI (C) nuclear foci formation was analyzed 
by immunofluorescence microscopy (IF). Quantification of the percentage of PTEN+/+ 
and PTEN-/- nuclei displaying greater than five discrete FANCD2 or FANCI nuclear foci 
reveals defective MMC-inducible FANCD2 and FANCI foci formation in PTEN-/- cells. 
***, P < 0.001. (D) Immunoblotting for FANCD2, FANCI, and RAD51 reveals no 
appreciable differences in total cellular levels of MMC-inducible FANCD2 and FANCI 
monoubiquitination or RAD51 between PTEN+/+ and PTEN-/- cells. Cells were incubated 
in the absence or presence of 200 nM MMC for 24 h and allowed to recover for 8 h. (E) 
Chromatin fractionation analysis of lysates from MCF10A PTEN+/+ and PTEN-/- cells 
reveals efficient localization of FANCD2, FANCI, and RAD51 to chromatin following 
MMC treatment. Cells were incubated in the absence (NT) or presence of 200 nM MMC 
for 24 h. W, unfractionated whole-cell lysate; S, soluble cytoplasmic and nuclear 
fraction; C, chromatin-enriched fraction. 
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Figure S3. Increased FANCM instability and defective chromatin recruitment of the 
FA core complex in PTEN-deficient cells 
(A) Immunoblotting analyses of whole-cell lysates from HCT116 PTEN+/+ and PTEN-/- 
cells reveal decreased levels of FANCM in PTEN-/- cells. Cells were incubated in the 
absence (NT) or presence of 40 nM mitomycin C (MMC) for 18 h and allowed to recover 
for up to 24 h. (B) Immunoblotting analyses of whole-cell lysates from MCF10A 
PTEN+/+ and PTEN-/- cells reveal decreased levels of FANCM in PTEN-/- cells. Cells 
were treated as described for (A). RBI, Relative protein band intensity. (C) MCF10A 
PTEN+/+ and PTEN-/- cells were incubated in the absence or presence of 40 µg/mL 
cycloheximide (CHX) alone or 40 µg/mL CHX and 4 µM MG132 (CHX + MG) for the 
indicated times. Whole-cell lysates were prepared and immunoblotted with anti-FANCM, 
anti-p53, and anti-PTEN antibodies. (D) Quantification of FANCM nuclear foci 
formation in HCT116 PTEN+/+ and PTEN-/- cells reveals a defect in MMC-inducible 
FANCM nuclear foci formation in PTEN-/- cells. Cells were incubated in the absence 
(NT) or presence of 40 nM MMC for 18 h. ***, P < 0.001. (E) Quantification of FANCA 
nuclear foci formation in HCT116 PTEN+/+ and PTEN-/- cells reveals reduced MMC-
inducible FANCA nuclear foci formation in PTEN-/- cells. Cells were treated as described 
for (D). ***, P < 0.001. (F) Chromatin fractionation analysis of HCT116 PTEN+/+ and 
PTEN-/- cells reveals a defect in the localization of FANCA to chromatin following MMC 
treatment. Cells were incubated in the absence (NT) or presence of 200 nM MMC for 24 
h. W, unfractionated whole-cell lysate; S, soluble cytoplasmic and nuclear fraction; C, 
chromatin fraction. (G) Defective MMC-inducible FANCM nuclear foci formation in 
HCT116 PTEN-/- cells. Cells were treated as described for (D). (H) Defective MMC- 
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inducible FANCA nuclear foci formation in HCT116 PTEN-/- cells. Cells were treated as 
described for (D). 
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Figure S4. PTEN does not dephosphorylate PLK1-phosphorylated FANCM in vitro 
FANCM was incubated in the presence of PLK1, 32P-ATP and increasing concentrations 
of PTEN or PTEN-C124S (lipid and protein phosphatase defective). SDS-PAGE was 
used to separate the proteins and phosphorylation levels were detected by exposing the 
dried gel to radiographic film. Lanes 5-7 show the input proteins in isolation. *, Indicates 
some minor contaminants within protein preparations, in particular a minor band in PLK1 
preparations runs at the same size as PTEN and is phosphorylated by PLK1 even in the 
absence of PTEN addition. Some PLK1 autophosphorylation also occurs. 
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Figure S5. Increased γH2AX and 53BP1 nuclear foci formation in PTEN-deficient 
cells 
(A) Quantification of γH2AX nuclear foci formation in MCF10A PTEN+/+ and PTEN-/- 
cells reveals constitutively elevated and persistent γH2AX nuclear foci in PTEN-/- cells. 
Cells were incubated in the absence (NT) or presence of 200 nM MMC for 18 h and 
allowed to recover for up to 24 h. ***, P < 0.001. (B) Quantification of 53BP1 nuclear 
foci formation in PTEN+/+ and PTEN-/- cells reveals elevated levels of 53BP1 nuclear foci 
in PTEN-/- cells with and without MMC treatment. Cells were treated as described for 
(A). *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) Chromatin fractionation analysis of 
HCT116 PTEN+/+ and PTEN-/- cells reveals increased 53BP1 chromatin localization in 
PTEN-/- cells with and without MMC treatment. Cells were incubated in the absence 
(NT) or presence of 40 nM MMC for 18 h. W, unfractionated whole-cell lysate; S, 
soluble cytoplasmic and nuclear fraction; C, chromatin fraction. (D and E) Quantification 
of RAD51 nuclear foci formation in HCT116 (D) and MCF10A (E) PTEN+/+ and PTEN-/- 
cells reveals no appreciable differences in the levels of RAD51 nuclear foci formation 
between PTEN+/+ and PTEN-/- cells. Cells were incubated in the absence (NT) or presence 
of 40 nM (HCT116) or 200 nM (MCF10A) MMC for 18 h and allowed to recover for up 
to 24 h (E). 
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Figure S6. PTEN function in ICL repair is protein phosphatase dependent 
(A) HCT116 PTEN-/- cells were stably transduced with pLenti6.2-LacZ, -PTEN-WT, -
PTEN-C124S, -PTEN-G129E, and -PTEN-Y138L. Whole-cell lysates were prepared and 
immunoblotted for PTEN, AKT, AKT pS473, RAD51, and α-tubulin. (B) PTEN-Y138L 
fails to rescue the sensitivity of PTEN-/- cells to the clastogenic effects of mitomycin C 
(MMC), in contrast to PTEN-WT. Cells were incubated in the absence (NT) or presence 
of 20 nM MMC for 24 h and metaphase spreads were analyzed for structural 
chromosome aberrations. ***, P < 0.001. (C and D) Defective FANCD2 (C) and FANCI 
(D) nuclear foci formation in PTEN-/- cells expressing PTEN-Y138L. Cells were 
incubated in the absence (NT) or presence of 200 nM MMC for 18 h. ***, P < 0.001. (E 
and F) Defective FANCA (E) and FANCM (F) nuclear foci formation in PTEN-/- cells 
expressing LacZ, PTEN-C124S, and PTEN-Y138L. Cells were incubated in the absence 
(NT) or presence of 200 nM MMC for 18 h. ***, P < 0.001. 
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Figure S7. FANCD2 and PTEN epistasis analysis 
(A) Metaphase chromosome analysis of FA-D2 (FANCD2-/-) cells reveals that 
knockdown of PTEN (siPTEN) does not lead to a further increase in the levels of 
complex chromosome aberrations. siCtrl, control, non-targeting siRNA. (B) siRNA-
mediated knockdown of FANCD2 in the PTEN-deficient prostate adenocarcinoma cell 
line PC-3. (C) Knockdown of FANCD2 (siFANCD2) in PC-3 cells does not lead to a 
further increase in sensitivity to MMC cytotoxicity. siCtrl, control, non-targeting siRNA. 
(D-F) Metaphase chromosome analysis of PC-3 cells reveals that knockdown of 
FANCD2 does not lead to a further increase in the levels of chromosome gaps and breaks 
(E), complex chromosome aberrations (F), or total chromosome aberrations (G). 
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Figure S8. Proposed model of the role of PTEN in ICL repair 
PTEN has previously been shown to be required for the assembly of APC/C-CDH1 and 
the degradation of PLK11. PLK1 directly phosphorylates PTEN, promoting its 
accumulation in chromatin2. In turn, PTEN dephosphorylates PLK1, leading to its 
inactivation and destabilization3. When PTEN is present, upon DNA damage, it 
dephosphorylates PLK1, which allows FANCM to promote the chromatin recruitment of 
FANCA and the FA core complex, resulting in efficient FANCD2 and FANCI nuclear 
foci formation and error-free ICL repair. In the absence of PTEN, PLK1 fails to be 
dephosphorylated, remains constitutively active and phosphorylates FANCM. FANCM 
phosphorylation leads to its ubiquitination and subsequent degradation by the 
proteasome. The FANCM phosphatase remains to be identified. When FANCM levels 
are low, the chromatin recruitment of FANCA and the FA core complex is attenuated, 
leading to inefficient FANCD2 and FANCI nuclear foci formation and error-prone ICL 
repair. A, FANCA; D2, FANCD2; I, FANCI; M, FANCM; P, phosphorylation; Ub, 
ubiquitination. Black- and grey-filled arrows indicate functional and non-functional steps, 
respectively. 
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Figure S9. Validation of the FANCM mouse monoclonal antibodies used in these 
studies 
293 cells were transfected with control non-targeting siRNA (lane 1) or siRNA targeting 
FANCM (lane 2). Whole-cell extracts were prepared in 10 mM Tris, 150 mM NaCl, 
10%v/v glycerol, 0.1%w/v Triton X-100, 2 U/mL benzonase. Proteins were resolved on 
NuPAGE 3-8% w/v Tris-Acetate gels (Invitrogen), transferred to polyvinylidene 
difluoride (PVDF) membranes, and immunoblotted with the indicated anti-FANCM 
mouse monoclonal antibodies.  
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APPENDIX III 
 
Supplemental information for manuscript III: “PTEN regulation by SUMOylation is 
important for its DNA crosslink repair” 
 
Supplemental Figures 
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Figure S1. PTEN-SUMO cellular localization 
(A and B) Cellular fractionation analysis on HeLa cells showed a stabilization of PTEN-
SUMO in the nucleus and bound to chromatin in the presence of MG132. This was 
visualized by two separate cell fractionation assays  (A) separating cytoplasmic (CS), 
nuclear soluble (NS) and chromatin bound (CB) and (B) a nuclear enrichment.  
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Figure S2. Proposed model of the role of PTEN SUMOylation in DNA repair 
It has been shown that PTEN is SUMOylated on K254 and this SUMOylation is 
important for its role in DNA repair, but how this modification results in genome stability 
is still unclear [1].  We propose PTEN dephosphorylates one or more DNA repair 
proteins regulating their activity. To ensure the correct kinetics of DNA repair, PTEN 
SUMOylation and its subsequent ubiquitination by RNF4 regulate PTENs protein levels 
in the nucleus. p97/VCP then removes PTEN and shuttles it to the proteasome through 
the interaction of the SUMO/Ub chains  and p97/VCP adapter proteins.  
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